

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Effectiveness of a multimodal prehabilitation program in patients with bladder cancer undergoing radical cystectomy: protocol of the ENHANCE multicenter randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-071304
Article Type:	Protocol
Date Submitted by the Author:	21-Dec-2022
Complete List of Authors:	<p>Akdemir, Emine; Antoni van Leeuwenhoek Nederlands Kanker Instituut, Department of Psychosocial Research and Epidemiology; Antoni van Leeuwenhoek Nederlands Kanker Instituut, Department of Center for Quality of Life</p> <p>Sweegers, Maike; Antoni van Leeuwenhoek Nederlands Kanker Instituut, Department of Psychosocial Research and Epidemiology; Antoni van Leeuwenhoek Nederlands Kanker Instituut, Department of Center for Quality of Life</p> <p>Vrieling, Alina; Radboud University Medical Center, Department for Health Evidence</p> <p>Rundqvist, Helene; Karolinska Institutet, Department of Laboratory Medicine</p> <p>Meijer, Richard; University Medical Center Utrecht, Department of Oncological Urology</p> <p>Leliveld-Kors, Annemarie; University Medical Centre Groningen, Department of Urology</p> <p>van der Heijden, Toine; Radboud University Medical Center, Department of Urology</p> <p>Rutten, Vera; Erasmus University Medical Center, Department of Urology, Erasmus MC Cancer Institute</p> <p>Koldewijn, Evert; Catharina Hospital, Department Urology</p> <p>Bos, Siebe; Noordwest Ziekenhuisgroep, Department of Urology</p> <p>Wijburg, Carl; Rijnstate Hospital, Department of Urology</p> <p>Marcelissen, Tom; Maastricht University Medical Centre+, Department of Urology</p> <p>Bongers, Bart; Maastricht University, Department of Nutrition and Movement Sciences, Nutrition and Translational Research in Metabolism (NUTRIM), Faculty of Health, Medicine and Life Sciences; Maastricht University, Department of Epidemiology, Care and Public Health Research Institute (CAPHRI), Faculty of Health, Medicine and Life Sciences</p> <p>Retèl, Valesca; Antoni van Leeuwenhoek Nederlands Kanker Instituut, Department of Psychosocial Research and Epidemiology; Erasmus University Rotterdam, Erasmus School of Health Policy and Management</p> <p>Van Harten, Wim; University of Twente, Department of Health Technology Services Research; Rijnstate Hospital</p> <p>May, Anne; University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care</p>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

	Groen , Wim ; Antoni van Leeuwenhoek Nederlands Kanker Instituut, Department of Psychosocial Research and Epidemiology; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Medicine for older people Stuiver, Martijn; Antoni van Leeuwenhoek Nederlands Kanker Instituut; Amsterdam Universitair Medische Centra, Epidemiology and Data Science
Keywords:	Urological tumours < ONCOLOGY, REHABILITATION MEDICINE, Nutritional support < ONCOLOGY, SURGERY



**TITLE PAGE****Title**

EffectiveNess of a multimodal preHAbilitation program in patieNts with bladder canCER undergoing radical cystectomy: protocol of the ENHANCE multicenter randomized controlled trial

**Authors and affiliations**

Emine Akdemir<sup>1,2</sup>, Maïke G. Sweegers<sup>1,2</sup>, Alina Vrieling<sup>3</sup>, Helene Rundqvist<sup>4</sup>, Richard P. Meijer<sup>5</sup>, Annemarie M. Leliveld-Kors<sup>6</sup>, Antoine G. van der Heijden<sup>7</sup>, Vera P. Rutten<sup>8</sup>, Evert L. Koldewijn<sup>9</sup>, Siebe D. Bos<sup>10</sup>, Carl J. Wijburg<sup>11</sup>, Tom A.T. Marcelissen<sup>12</sup>, Bart C. Bongers<sup>13,14</sup>, Valesca P. Retel<sup>1,15</sup>, Wim. H. van Harten<sup>1,16,17</sup>, Anne M. May<sup>18</sup>, Wim G. Groen<sup>1,19,20,21\*</sup>, Martijn M. Stuiver<sup>1,2,22,23</sup>

Correspondence to dr. Martijn M. Stuiver; [m.stuiver@nki.nl](mailto:m.stuiver@nki.nl)

<sup>1</sup> Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

<sup>2</sup> Center for Quality of Life, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

<sup>3</sup> Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands

<sup>4</sup> Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden

<sup>5</sup> Department of Oncological Urology, University Medical Center Utrecht, Utrecht, The Netherlands

<sup>6</sup> Department of Urology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands

<sup>7</sup> Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands

<sup>8</sup> Department of Urology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands

<sup>9</sup> Department of Urology, Catharina Hospital, Eindhoven, The Netherlands

<sup>10</sup> Department of Urology, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands

<sup>11</sup> Department of Urology, Rijnstate Hospital, Arnhem, The Netherlands

<sup>12</sup> Department of Urology, Maastricht University Medical Center+, Maastricht, The Netherlands

<sup>13</sup> Department of Nutrition and Movement Sciences, Nutrition and Translational Research in Metabolism (NUTRIM), Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands

<sup>14</sup> Department of Epidemiology, Care and Public Health Research Institute (CAPHRI), Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands

<sup>15</sup> Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands

<sup>16</sup> Department of Health Technology and Services Research, University of Twente, Enschede, The Netherlands

1  
2  
3 <sup>17</sup> Rijnstate Hospital, Arnhem, The Netherlands

4 <sup>18</sup> Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht,  
5  
6 The Netherlands

7 <sup>19</sup> Department of Medicine for older people, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117,  
8  
9 1081 HV Amsterdam, The Netherlands

10 <sup>20</sup> Amsterdam Public Health Research Institute, Aging & Later Life, Amsterdam, The Netherlands

11 <sup>21</sup> Amsterdam Movement Sciences, Ageing & Vitality, Rehabilitation & Development, Amsterdam, The Netherlands

12 <sup>22</sup> Department of Epidemiology and Data Science, Amsterdam Public Health, Amsterdam University Medical Centers,  
13  
14 Location Academic Medical Center, Amsterdam, The Netherlands

15 <sup>23</sup> Centre of Expertise Urban Vitality, Faculty of Health, Amsterdam University of Applied Sciences, Amsterdam, The  
16  
17 Netherlands

18  
19  
20 \* MMS and WG contributed to this work equally, shared last author.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Introduction** Radical cystectomy (RC) is the standard treatment for patients with non-metastatic muscle-invasive bladder cancer, as well as for patients with therapy refractory high-risk non-muscle invasive bladder cancer. However, 50-65% of patients undergoing RC experience perioperative complications. The risk, severity, and impact of these complications is associated with a patient's preoperative cardiorespiratory fitness, nutritional and smoking status, and presence of anxiety and depression. There is emerging evidence supporting multimodal prehabilitation as a strategy to reduce the risk of complications and improve functional recovery after major cancer surgery. However, for bladder cancer the evidence is still limited. The aim of this study is to investigate the superiority of a multimodal prehabilitation program versus standard-of-care in terms of reducing perioperative complications in patients with bladder cancer undergoing RC.

**Methods and analysis** This multicenter, open label, prospective, randomized controlled trial, will include 154 patients with bladder cancer undergoing RC. Patients are recruited from eight hospitals in The Netherlands and will be randomly (1:1) allocated to the intervention group receiving a structured multimodal prehabilitation program of approximately 4-6 weeks, or to the control group receiving standard-of-care. The primary outcome is the proportion of patients who develop one or more grade  $\geq 2$  complications (according to the Clavien-Dindo classification) within 90 days of surgery. Secondary outcomes include cardiorespiratory fitness, length of hospital stay, health-related quality of life, tumor tissue biomarkers of hypoxia, immune cell infiltration, and cost-effectiveness. Data collection will take place at baseline, before surgery, and 4 and 12 weeks after surgery.

**Ethics and dissemination** Ethical approval for this study was granted by the Medical Ethics Committee NedMec (Amsterdam, The Netherlands) under reference number 22-595/NL78792.031.22. Results of the study will be published in international peer-reviewed journals.

**Trial registration number** Clinical Trials (NCT05480735). Prospectively registered on 29 July 2022.

**STRENGTHS AND LIMITATIONS OF THIS STUDY**

- This multicenter randomized controlled trial will provide firm empirical evidence regarding the efficacy of multimodal prehabilitation in patients with bladder cancer undergoing radical cystectomy, a population that is currently understudied.
- This is the first prehabilitation study in bladder cancer to include a cost-effectiveness analysis, which will support decisions regarding implementation and reimbursement of prehabilitation in daily clinical practice.
- This is the first study to investigate the effects of prehabilitation on tumor hypoxia and immune cell infiltration in patients with bladder cancer.
- The intervention accounts for heterogeneity in cancer treatment by offering additional support during neoadjuvant treatment when appropriate.
- Due to the two-group design and the multimodal intervention, it will not be possible to disentangle the independent effects of physical exercise training, nutritional support, psychological counseling, and smoking cessation.

## INTRODUCTION

Bladder cancer is the 10<sup>th</sup> most common diagnosed cancer worldwide, with over 573,000 new patients and 213,000 deaths each year [1]. Radical cystectomy (RC) is the standard treatment for patients with non-metastatic muscle-invasive bladder cancer [2, 3], as well as for patients with therapy refractory high-risk non-muscle invasive bladder cancer [4]. RC is a challenging and costly surgical procedure with high morbidity and mortality rates [5]: 50-65% of the patients experience perioperative complications, of which 10-20% are high-grade [6-8]. Low cardiorespiratory fitness [9, 10], poor nutritional status [11], the presence of anxiety and depression [12], and smoking [13] increase the risk of perioperative complications, length of hospital stay, and the associated medical costs [9, 10]. In daily clinical practice, 25% of patients with muscle-invasive bladder cancer receive neoadjuvant treatment, which might further impair preoperative cardiorespiratory fitness and nutritional status [14-17].

Emerging evidence has identified the preoperative period as a window of opportunity to address lifestyle. Multimodal preoperative interventions, including physical exercise training, nutritional support, psychological counseling and smoking cessation, that aim to increase a patient's tolerance to surgery, reduce the incidence, severity, and impact of complications, accelerate and improve the quality of recovery, and improve quality of life have been termed *prehabilitation*.

To date, no adequately powered trial has been performed to establish the effectiveness of a multimodal prehabilitation program for reducing the incidence, severity, and impact of complications and costs associated with RC for bladder cancer. A few studies investigated the impact of a single modal [20, 21] or multimodal [18, 19] prehabilitation program on functional recovery following RC. A phase I/II trial with 54 patients showed improvement in patient-reported quality of life after four weeks of a supervised physical exercise training program before surgery [21]. A feasibility randomized controlled trial with 60 patients provided evidence that a 3- to 6-week supervised vigorous aerobic exercise training program before surgery led to improvements in cardiorespiratory fitness parameters and possibly fewer surgical complications [20]. A randomized controlled trial with 107 patients demonstrated improvement in walking distance during seven days after surgery [18] and improved muscle power [22]. Finally, a randomized controlled trial with 70 patients showed significant better functional capacity in the intervention group that followed a multimodal program compared to the control group, at four weeks after surgery [19]. However, the physical exercise intervention in these studies including patients with bladder cancer had limitations with regard to therapeutic validity [23] due to a short duration of the



1  
2  
3 intervention [18, 22], relatively low exercise intensity [18, 19, 22], or only patient reported compliance  
4 with the exercise intervention [18, 19, 22].  
5

6  
7 Preclinical studies indicate that exercise may directly affect tumor characteristics such as normalization of  
8 tumor vasculature and immune cell infiltration, thereby enhancing tumor perfusion and reducing hypoxia  
9 [24, 25]. These factors are associated with treatment efficacy and survival [26-28]. The current study  
10 provides a unique opportunity to explore the effects of prehabilitation on tumor inflammation and  
11 hypoxia markers, which has not yet been studied in human patients.  
12  
13  
14

### 15 16 **Study objectives**

17 The ENHANCE study is designed to investigate the effectiveness of a multimodal prehabilitation program  
18 versus standard-of-care in patients approaching RC. The primary aim is to investigate the superiority of a  
19 multimodal prehabilitation program in terms of reducing one or more grade  $\geq 2$  perioperative  
20 complications within 90 days in patients with bladder cancer undergoing RC. Secondary outcomes include  
21 changes in preoperative cardiorespiratory fitness, length of hospital stay, health-related quality of life,  
22 tumor tissue biomarkers of hypoxia, immune cell infiltration, and cost-effectiveness.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## METHODS AND ANALYSIS

The ENHANCE study is a multicenter, open label, two-arm randomized controlled trial. Patient inclusion and data collection started in August 2022. Ethical approval extending to all centers was granted by the Medical Ethical Committee NedMec (Amsterdam, The Netherlands), under reference number 22-595/NL78792.031.22. The trial is prospectively registered in Clinical Trials (NCT05480735) on 29 July 2022.

### Study population

The study aims to include 154 patients who meet the following inclusion criteria: aged  $\geq 18$  years, histologically confirmed, primary, bladder cancer (cTa-4N0-3M0), and planned to undergo RC. Patients with severe cognitive or psychiatric disorders, patients with a contraindication to perform physical exercise training or a cardiopulmonary exercise test (CPET), patients undergoing surgery within 4 weeks, and patients unable to read or understand the Dutch language will be excluded.

### Recruitment and randomization

Patients are recruited from eight academic or teaching hospitals across different regions in The Netherlands (Catharina Hospital, Erasmus Medical Center, Maastricht University Medical Center+, Noordwest Hospital Group, Radboud University Medical Center, Rijnstate Hospital, University Medical Center Groningen, and University Medical Center Utrecht). The Netherlands Cancer Institute is the coordinating center. After establishment of diagnosis and indication for surgery, the urologist or nurse specialist invites patients to participate in the study and provides the patient information letter. The study coordinator contacts these patients to provide further oral information and answer potential questions about the study. When a patient agrees to participate, written informed consent is obtained. After collection of baseline data, patients are randomized in a 1:1 ratio, using a minimization algorithm [29] aimed to achieve optimal balance between the two study arms with regard to the recruiting hospital, neoadjuvant treatment (yes/no), nodal status (N0/N1-3), and type of surgery (open/robot-assisted RC). Minimization is done using the Minirand package in R 4.0.4 [30, 31]. The algorithm includes a random component to ensure blinding of treatment allocation. Due to the nature of the intervention, blinding of participants and research investigators is not possible. After randomization, patients in both the intervention and control groups receive a leaflet with recommendations on physical activity, diet and smoking cessation, according to the latest guidelines for patients with cancer [32, 33]. These recommendations are not further individualised or actively supported.

1  
2  
3 Patients who do not wish to participate in the study are asked to participate in a one-time questionnaire  
4 as described in Table 1. A participant flow diagram is shown in Figure 1.  
5  
6

### 7 **Control group– standard-of-care**

8 Patients randomized to the standard-of-care arm receive care as usual, which does not include a  
9 comprehensive multimodal prehabilitation program. In all participating centers, enhanced recovery  
10 after surgery protocols are used to optimize medical conditions to enhance recovery [34]. These  
11 protocols include advice on smoking cessation when a patient is smoking and a referral to a dietician  
12 when malnutrition is detected. Preoperatively, the urologist determines whether or not the patient is  
13 physically fit for surgery. Participants in the control group are not prohibited to be physically active or  
14 seek counselling for nutritional advice, psychological support, or smoking cessation.  
15  
16  
17  
18  
19  
20

### 21 **Intervention group– prehabilitation**

22 Patients randomized to the intervention arm will participate in a multimodal prehabilitation program  
23 including supervised physical exercise training, nutritional support, and – when relevant – psychological  
24 counseling and professional support for smoking-cessation, to enhance their health status. The  
25 intervention starts as soon as possible after baseline measurements and randomization, approximately  
26 4-6 weeks before surgery, and is continued until surgery. Patients who are included before undergoing  
27 neoadjuvant treatment (including chemotherapy and immunotherapy) will participate in a physical  
28 exercise training program from inclusion until completion of neoadjuvant treatment to prevent the  
29 often observed decline in physical fitness throughout neoadjuvant therapy. Subsequently, these patients  
30 will participate in the full multimodal prehabilitation program until the date of surgery. Adverse events  
31 related to the intervention are monitored.  
32  
33  
34  
35  
36  
37  
38  
39

### 40 ***Physical exercise training program***

41 The physical exercise training program consists of three training sessions per week under the  
42 supervision of a physical therapist. An overview of the training program and training progression is  
43 described in Table 2. The program will be delivered at a physical therapy practice near a patient's home  
44 to minimize travel time, preferably supervised by a physical therapist affiliated with Onconet, a  
45 nationwide network of physical therapists with additional competencies in cancer care. The study  
46 coordinator provides the physical therapists instructions via a video call covering the specifics of the  
47 training program for the current study.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Training sessions last one hour and consist of individualized aerobic interval training (three times a  
4 week), resistance training (two times a week), and relaxation exercises (once a week). Results of the  
5 CPET will be used to establish the individual training intensity for aerobic interval training. For the  
6 resistance training, six large muscle groups will be targeted, in two sets of a defined maximum number  
7 of repetitions. The aim of these training sessions is to improve cardiorespiratory fitness, and muscle  
8 strength and mass. Relaxation exercises consist of breathing exercises and progressive muscle relaxation  
9 [35], which will be instructed and guided by the physical therapist. The aim of these exercises is to  
10 reduce possible anxiety and stress. In addition to the supervised sessions, patients are encouraged to be  
11 moderately active on at least two additional days per week for 30 minutes.  
12  
13

14  
15 Patients who are included before starting neoadjuvant treatment receive additional training sessions  
16 during the neoadjuvant treatment period. The supervised sessions aim at preventing loss of physical  
17 fitness, and consist of twice-weekly moderate-intensity aerobic and resistance training. Patients receive  
18 the physical exercise training program as described above for the remaining 4-6 weeks before surgery.  
19  
20  
21  
22  
23  
24  
25

### 26 ***Nutritional support***

27  
28 Patients receive tailored advice from a registered dietician at the participating hospitals aiming at a total  
29 protein intake of 1.9-2.3 g/per kg of fat-free mass as estimated with bioelectrical impedance analysis, to  
30 promote an anabolic state. Dietary advice will emphasize the benefit of spreading protein consumption  
31 over three meals, with a goal of 25-30 g protein per meal, and includes advice for optimal energy intake.  
32 To achieve this, and to increase adaptive responses of the skeletal muscle, participants will receive high-  
33 quality protein supplements containing 30 g of whey protein, 20 microgram of vitamin D, and 250 mg of  
34 calcium [36] in standardized supplements produced for the purpose of the study (FrieslandCampina, The  
35 Netherlands). These supplements are prescribed after each physical exercise training session and daily  
36 at least one hour before sleep or in the morning (depending on the patient's preference). The dietician  
37 provides intake consultation and one or two follow-up sessions to evaluate nutritional intake.  
38  
39  
40  
41  
42  
43  
44

45 Nutritional support starts at 4-6 weeks before surgery for all patients.  
46

### 47 ***Psychological counseling***

48  
49 Patients are screened for anxiety and depression using the hospital anxiety and depression scale (HADS)  
50 questionnaire at baseline [37]. If a patient's score falls between 11 and 18, the option of psychological  
51 counselling is discussed and referral is arranged for patients indicating a need for such counselling.  
52  
53

54 Patients who score  $\geq 19$  are directly referred to psychological counselling. Referred patients receive an  
55  
56  
57  
58  
59  
60

1  
2  
3 initial counselling session of 1.5 hours, and additional sessions at the discretion of the psychological  
4 counsellor and the patient.  
5

### 6 7 ***Smoking cessation***

8 Intensive counselling and nicotine replacement therapy is offered to all smoking patients in the 4-6  
9 weeks before surgery. Counselling includes at least one in-person session and one or more telephone or  
10 in-person follow-up sessions by trained counsellors. If the patient indicates to be smoking and is willing  
11 to quit, the treating physician will refer the patient.  
12  
13  
14

### 15 16 **Study outcomes**

17 Data are collected before randomization (T0a), before surgery (T1), and 4 (T2), and 12 (T3) weeks after  
18 surgery. If applicable, additional data will be collected after neoadjuvant treatment (T0b). At T0a, clinical  
19 data (e.g., treatment, clinical stage) will be abstracted from the medical records and sociodemographic  
20 characteristics (e.g., age, sex, education) will be obtained via a questionnaire. In addition, coping  
21 mechanisms [38] will be assessed via a questionnaire as this can help understand participation,  
22 attendance, and dropouts. Data is collected in CastorEDC and access is restricted to the investigator  
23 team. Due to the low-risk of the intervention a data safety monitoring board is not instated.  
24  
25  
26  
27  
28  
29

### 30 31 ***Primary outcome***

32 The primary outcome is the proportion of patients who develop one or more grade  $\geq 2$  perioperative  
33 complications within 90 days after surgery. Complications are graded according to the Clavien-Dindo  
34 classification system [39] as described in Table 3.  
35  
36  
37

### 38 39 ***Secondary outcomes***

40 Secondary outcomes are the proportion of patients who develop one or more high-grade (grade  $\geq 3$ )  
41 complications, total number of complications, length of hospital stay, number of readmissions, disease  
42 status (progression/recurrence), and additional treatment within 90 days. Secondary outcomes also  
43 include the intermediate outcomes of the intervention: cardiorespiratory fitness (measured using the  
44 standardized CPET [40]), physical functioning, upper and lower extremity (functional) muscle strength,  
45 nutritional intake, nutritional status, body composition, health-related quality of life, bladder cancer-  
46 related quality of life, anxiety and depression, fatigue, physical activity, and adherence to the  
47 intervention. Direct and indirect costs are collected for the cost-effectiveness analysis. Tumor hypoxia,  
48 immune cell infiltration, and pathological response are assessed as explorative outcomes. Participants  
49 in the control group will be asked whether they participated in any (structured) lifestyle program during  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 the preoperative period, to monitor contamination. In both groups, participants will be asked whether  
4 they received any postoperative intervention. The timing and type of outcome measures are presented  
5 in Table 1.  
6  
7

### 8 *Compliance*

9  
10 To monitor therapeutic validity, compliance with the physical exercise training program is assessed by  
11 attendance rates and compliance to all parts of the training program as scored by the physical therapist  
12 on standardized training session forms, as well as by patient self-report via an activity diary. Compliance  
13 to nutritional supplement intake is assessed via a diary. Whether smoking cessation has been successful  
14 is assessed through questionnaires.  
15  
16  
17  
18

### 19 *Satisfaction*

20  
21 Patients in the intervention group are asked to complete a short questionnaire at the end of the study  
22 about the perceived effectiveness of and satisfaction with the program, whether they would suggest any  
23 changes, and whether they would recommend it to other patients with bladder cancer. In addition,  
24 patients will be asked if they are willing to be contacted for participation in a focus group where the  
25 intervention program and changes that may positively affect implementation will be further discussed.  
26  
27  
28  
29  
30

### 31 **Sample size calculation**

32  
33 Previous studies in diverse types of cancer reported a reduction of postoperative complications in the  
34 intervention group compared to the control group, with odds ratios ranging from 0.11 to 0.88 [41-47].  
35 This study aims to reduce the number of patients with any grade  $\geq 2$  perioperative complication within  
36 90 days from 60% [48, 49] to 35% (relative risk 0.58, odds ratio 0.36) [50, 51]. Assuming a two-sided  
37 Fisher exact test with a power of 80% and an alpha of 0.05, in total 140 patients will be needed. To  
38 account for 10% dropout, including dropout due to cancelling of the planned surgery, 154 patients will  
39 be included. Approximately 380 patients with bladder cancer undergo RC in the eight participating  
40 hospitals annually. This implies that it is feasible to complete inclusion within two and a half years, if  
41 recruitment rate is at least 17%.  
42  
43  
44  
45  
46  
47  
48

### 49 **Statistical analysis**

#### 50 *Primary outcome*

51  
52 All analyses will be performed on an intention-to-treat basis. Descriptive statistics will be calculated to  
53 describe and evaluate the comparability of the two groups at baseline on sociodemographic and clinical  
54 variables, and to assess the adequacy of the randomization. Patients who do not receive the planned  
55  
56  
57  
58  
59  
60

1  
2  
3 surgery or have an open-closed procedure, independent of group allocation, will be excluded from the  
4 primary analysis. The proportion of patients who develop any grade  $\geq 2$  complications will be compared  
5 in the two study arms by using Fisher's exact test and a Poisson regression model with a log link,  
6  
7 adjusted for the stratification factors and relevant baseline imbalances. The relative risk will be reported  
8  
9 with a 95% confidence interval based on robust standard errors [52].  
10

### 11 12 *Secondary study outcomes*

13  
14 Between-group differences over time will be evaluated in measures of physical functioning and patient-  
15 reported outcomes using linear mixed effects regression analysis. For high-grade complications, length  
16 of hospital stay, and number of readmissions, Poisson regression models with an appropriate link  
17 function will be used. For continuous outcomes, differences in mean change scores between the two  
18 study arms will be accompanied by effect sizes. Standardized effect sizes will be calculated by  
19 subtracting the mean change scores of the control group from those of the intervention group, and  
20 subsequently dividing this by the pooled standard deviation. Effect sizes of 0.2 are considered small, 0.5  
21 moderate, and 0.8 large [53]. A  $p$ -value  $< 0.05$  will be considered statistically significant.  
22  
23  
24  
25  
26  
27

### 28 *Intervention fidelity*

29  
30 Descriptive statistics will be used to summarize compliance rates of the supervised exercise sessions as  
31 well as home based physical activity, supplement consumption, and smoking cessation. Compliance  
32 rates are based on number of completed training sessions, supplementation consumption, and number  
33 of patients who stop smoking in the study intervention. Whether the level of compliance is associated  
34 with changes over time in primary and secondary study outcomes will be evaluated using generalized  
35 linear mixed effects models.  
36  
37  
38  
39

### 40 *Non-participants*

41  
42 Baseline data of participants will be compared to those of non-participants using chi-squared statistics  
43 for categorical variables and analysis of variance for continuous variables.  
44  
45

### 46 *Exploratory analysis*

47  
48 Exploratory subgroup analyses will be performed to explore a potential difference in effectiveness of the  
49 physical exercise training program between those who received neoadjuvant chemotherapy and those  
50 who did not. This will be done by adding an interaction term to the model and by performing stratified  
51 analyses if the interaction term is statistically significant at  $p < 0.10$ . Exploratory analyses will also be  
52 executed to study the relationship of post-intervention/preoperative physical fitness parameters (i.e.,  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 VO<sub>2</sub>peak) and nutritional status, with perioperative outcomes (grade  $\geq 2$  complications yes/no and  
4 number of days in the hospital). For this analysis, univariable and multivariable Poisson regression  
5 analyses will be used.  
6  
7

### 8 9 **Economic evaluation**

10 A trial- and model-based economic evaluation will be performed, based on the intention-to-treat  
11 analysis. The model-based evaluation will use literature for the potential long-term consequences and  
12 parametric survival methods to extrapolate the trial data beyond the included follow-up. The analysis  
13 will be approached from a societal perspective of The Netherlands and a lifelong time horizon, using a  
14 Markov decision model. Outcomes are 1) the incremental costs per reduced proportion of patients who  
15 develop one or more grade  $\geq 2$  perioperative complications within 90 days (trial-based), and 2)  
16 incremental costs, incremental quality-adjusted life years, and the incremental cost-effectiveness ratio  
17 (ICER) (model-based). An estimation of the degree of uncertainty around each input parameter will be  
18 included with the use of probabilistic sensitivity analyses. Parameter values will be drawn randomly  
19 from the assigned distributions, using Monte Carlo simulations [54]. To capture necessary support  
20 regarding adoption and further research, value of information (VOI) analyses will be performed [55].  
21 Where appropriate, Dutch guidelines for costing studies will be used in applying tariffs to units of  
22 resource use [56]. Finally, a budget impact analysis will be performed according to the ISPOR guidelines  
23 [57].  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33

### 34 35 **Patient and public involvement**

36 Patients or the public were not involved in the development of the study design. A patient  
37 representative is currently involved in the study and input will be obtained whenever relevant during  
38 the trial. Annual consortium meetings with the urologists are organized.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## DISCUSSION

A considerable proportion of patients with bladder cancer scheduled for RC has a poor cardiorespiratory fitness [9, 10], is malnourished [11, 58], and/or is an active smoker at diagnosis [59]. This implies that there is a substantial potential for improving cardiorespiratory fitness and nutritional status in this patient population. Here, the rationale and design of a multimodal prehabilitation program for patients with bladder cancer who are scheduled for RC is presented. It is hypothesized that the program will be effective in reducing the number and severity of perioperative complications.

This study has several strengths, including its multicenter, randomized design, the use of an intention-to-treat basis for the data analysis, and a minimization technique to ensure blinded treatment allocation and comparable groups. Most importantly, the study intervention consists of a tailored program for physical exercise training and nutritional support following current best-practice for prehabilitation. Moreover, a cost-effectiveness analysis will be performed to anticipate smooth implementation and reimbursement, and tumor hypoxia and immune cell infiltration analysis will be performed exploratively. Intervention fidelity will be monitored in detail, as recommended previously [60], as will adverse events related to the intervention. Another notable strength is the additional analysis in non-participants. Selective non-participation is a serious risk for the generalizability of physical exercise training studies. Previous physical exercise training studies in other cancer populations have shown relevant differences between those who participate and those who do not [61, 62]. It has previously been described that patients who were eligible for prehabilitation programs for colon cancer surgery expressed several reservations [63]. It is vital to understand the characteristics of non-participants and reasons for non-participation in bladder cancer prehabilitation. This will not only help judge the generalizability of the results but will also support implementation in a way that will maximize the potential value of the prehabilitation program and achieve equitable health outcomes. Finally, the exploratory subgroup analysis in patients who receive neoadjuvant treatment might be relevant to inform future studies on risk stratification.

To limit barriers to participation and adherence, the exercise program will be delivered as near to the patients' homes as possible, to minimize travel time. This is a very important factor for patients with cancer according to previous studies [51, 64-66]. The availability of and close collaboration with the nationwide Onconet network of physical therapists, who are specifically educated to supervise patients with cancer, is an important advantage. An additional benefit of this approach is that it will facilitate implementation if the intervention proves to be effective.

1  
2  
3 This study also has some limitations. Patients with bladder cancer will be followed for a period of 90  
4 days after surgery, meaning that longer-term evaluation of outcomes will not be possible. Because up to  
5 60% of patients report complications within 90 days after surgery [67], it is expected that the time frame  
6 will be adequate for our primary outcome. A possible limitation is the risk of contamination in the  
7 control group. An evaluation questionnaire will be used in the control group to determine whether  
8 patients were physically active or received a (structured) lifestyle intervention pre- and postoperatively.  
9 Although objective measurements of habitual physical activity may provide a more detailed insight into  
10 physical activity levels not prone to recall bias, the collection of physical activity levels will be restricted  
11 to using questionnaires for feasibility reasons. This program is designed to maximally improve a patient's  
12 health status by including physical exercise training, nutritional support, psychological counseling and  
13 smoking cessation. It is not likely that patients who are randomized to the control group would initiate a  
14 program consisting of all these components on their own. The multimodal approach prohibits  
15 disentangling of the individual effects of each lifestyle component in the prehabilitation program.  
16 Considering the number of intervention components and the prevalence of bladder cancer, a larger  
17 study using a full factorial design is unlikely to be feasible in this population. Moreover, the current best-  
18 practice for other types of cancer supports the use of multimodal interventions over unimodal  
19 approaches [68, 69]. Higher levels of physical exercise training have been demonstrated to be beneficial  
20 for both cancer prevention and, in some solid tumors, progression of disease and cancer-related  
21 mortality [70, 71]. However, the underlying biological mechanism has yet to be demonstrated. It is  
22 expected that the prehabilitation program has positive effects on the tumor microenvironment. The  
23 hypoxic tumor microenvironment is a common characteristics of a solid tumor when oxygen levels  
24 become low, as a result of the rapid proliferation of tumor cells [72] and is linked to poor prognosis in  
25 bladder cancer [73]. Physical exercise training has regulatory effects on the angiogenesis of skeletal  
26 muscles, which has raised interest in whether these effects might translate to solid tumors [74].  
27 Preclinical research has shown that training may acutely reduce tumor hypoxia through vascular  
28 normalization and thereby improve the perfusion of tumor tissue [75-78]. In addition, exercise training  
29 has been suggested to alter immune cell infiltration in solid tumors and thereby contribute to enhanced  
30 immune surveillance and improved vascular function [25]. However, current evidence is inconsistent  
31 and inconclusive [79]. Clinical trials are very limited and this preoperative setting provides an excellent  
32 opportunity to investigate the potential role of prehabilitation on tumor hypoxia and immune cell  
33 infiltration.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 To summarize, this study will provide empirical evidence on the benefits of multimodal prehabilitation  
4 for patients with bladder cancer planned for RC who are at high risk of perioperative complications and  
5 a long recovery period. When proven (cost-)effective, the study results will support implementation of a  
6 multimodal prehabilitation program for patients with bladder cancer in daily clinical practice.  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

### Author affiliations

- <sup>1</sup> Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
- <sup>2</sup> Center for Quality of Life, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
- <sup>3</sup> Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands
- <sup>4</sup> Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden
- <sup>5</sup> Department of Oncological Urology, University Medical Center Utrecht, Utrecht, The Netherlands
- <sup>6</sup> Department of Urology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands
- <sup>7</sup> Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands
- <sup>8</sup> Department of Urology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands
- <sup>9</sup> Department of Urology, Catharina Hospital, Eindhoven, The Netherlands
- <sup>10</sup> Department of Urology, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands
- <sup>11</sup> Department of Urology, Rijnstate Hospital, Arnhem, The Netherlands
- <sup>12</sup> Department of Urology, Maastricht University Medical Center+, Maastricht, The Netherlands
- <sup>13</sup> Department of Nutrition and Movement Sciences, Nutrition and Translational Research in Metabolism (NUTRIM), Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands
- <sup>14</sup> Department of Epidemiology, Care and Public Health Research Institute (CAPHRI), Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands
- <sup>15</sup> Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands
- <sup>16</sup> Department of Health Technology and Services Research, University of Twente, Enschede, The Netherlands
- <sup>17</sup> Rijnstate Hospital, Arnhem, The Netherlands
- <sup>18</sup> Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
- <sup>19</sup> Department of Medicine for older people, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
- <sup>20</sup> Amsterdam Public Health Research Institute, Aging & Later Life, Amsterdam, The Netherlands
- <sup>21</sup> Amsterdam Movement Sciences, Ageing & Vitality, Rehabilitation & Development, Amsterdam, The Netherlands
- <sup>22</sup> Department of Epidemiology and Data Science, Amsterdam Public Health, Amsterdam University Medical Centers, Location Academic Medical Center, Amsterdam, The Netherlands
- <sup>23</sup> Centre of Expertise Urban Vitality, Faculty of Health, Amsterdam University of Applied Sciences, Amsterdam, The Netherlands

### Authors' contributions

AV, AL, AH, EK, VPR, WH, AM, WG, and MMS conceived the study. AV, WH, AM, WG, MMS, MGS, and EA contributed to the design of the study protocol. RM, AL, AH, VCR, EK, SB, CW, TM, and BB reviewed the study protocol with a clinical perspective. VPR wrote the statistical approach of the economic evaluation. HR composed the protocol of tumor hypoxia and immune cell infiltration analysis. AV, WH, AM, WG, MMS, MGS, and EA wrote the manuscript. All authors read, commented on, and approved the manuscript.

### Funding

This work was supported by the Dutch Cancer Society (KWF, Delflandlaan 17, 1062 EA, Amsterdam, The Netherlands), grant number NKI 2020-1/12877. The funder has no role in the design, data collection, and analysis of the study.

### Acknowledgements

The protein supplements in the clinical study will be kindly provided by FrieslandCampina.

### Competing interests

CW received a research grant from ZonMw and gives courses on robot assisted radical cystectomy during conferences entitled with EAU. TM received consulting fees as member of the advisory board prostate cancer of Janssen-Cilag B.V.. BB participates on a Data Safety Monitoring Board of an international prehabilitation study, is board member of Netherlands Society of Human Movement sciences, member of Exercise is Medicine of Vereniging voor Sportgeneeskunde, and member of the Scientific Committee of Fit4Surgery. RM received research grants from Janssen, Roche and Astellas, an educational grant from Merck, received consulting fees from Merck, MSD, Janssen, Bristol-Myers Squibb Company, received support for attending the 2022 Global Congress on Bladder Cancer, and is EAU Panel member of the Muscle Invasive Bladder Cancer Guideline. MMS is member of the Scientific Committee of Fit4Surgery and board member of Onconet.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Patient consent for publication**  
Not applicable.

For peer review only

Table 1. Outcome measures in the intervention and control group

Description of outcome	Assessment	Description of measure	T0a	T0b	T1	T2	T3
<b>Primary outcome</b>							
Proportion of patients who develop one or more grade $\geq 2$ perioperative complications within 90 days	Perioperative complications, Grade $\geq 2$ according to Clavien Dindo classification	Number of grade $\geq 2$ complication is abstracted from medical records				X	X
<b>Secondary outcomes</b>							
Proportion of patients who develop one or more high-grade ( $\geq 3$ ) complications, number of complications, length of hospital stay, and readmissions within 90 days	Perioperative complications, Grade $\geq 3$ according to Clavien Dindo classification, length of hospital stay, readmissions	Number of grade $\geq 3$ complications, number of complications, length of hospital stay in days, and readmissions abstracted from medical records				X	X
Cardiorespiratory fitness	Cardiopulmonary exercise test (CPET) on a cycle ergometer using a ramp protocol [40]	Peak oxygen uptake ( $VO_2$ peak in ml/kg/min)	X		X		
Physical functioning	Short physical performance battery (SPPB) [80]	5 items organized into three subscales of balance, walking speed, and lower extremity muscle strength	X		X		X
Upper extremity muscle strength	Handgrip strength using a handheld dynamometer [81]	The maximum score of three attempts of both hands in kilogram (kg)					
Lower extremity functional muscle strength	30-second sit-to-stand test [82]	The number of sit to stands within 30 seconds	X		X		X
Nutritional intake	24-h recall	Protein (total gram) and caloric intake (total kcal)	X		X		
Nutritional status	Patient-generated subjective global assessment short form (PG-SGA SF) [83]	4 items assessing weight (status), nutritional intake, symptoms, and physical functioning	X	X	X	X	X
	Nil per mouth consumption during hospitalization	The number of days after RC abstracted from medical records				X	X
Body composition	Bioelectrical impedance analysis	Body mass (kg), body height (cm), (subcutaneous) fat mass (%), and (upper limb) muscle mass (kg) are measured, and BMI ( $kg/m^2$ )	X		X		X
Health-related quality of life	EORTC quality of life questionnaire core 30 (QLQ-C30) [84]	30 items, organized into 5 functional scales (physical, role, emotional, cognitive, social), 3 symptom scales (pain, fatigue, and emesis), 6 items (dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial impact), and an overall QoL scale	X	X	X	X	X
Bladder cancer-related quality of life	EORTC muscle-invasive bladder cancer specific module (BLM-30) [85]	30 items, assessing urinary symptoms, bowel symptoms, sexual functioning, urostomy problems, difficulties associated with the use of a catheter and body image	X	X	X	X	X
Anxiety and depression	Hospital anxiety and depression scale (HADS) [37]	7 items assessing anxiety and 7 items assessing depression	X	X	X	X	X
Fatigue	Multidimensional fatigue inventory (MFI) [86]	20 items, categorized into five scales: general fatigue, physical fatigue, reduced activity, reduced motivation, and mental fatigue	X	X	X	X	X
Physical activity	Short questionnaire to assess health-enhancing physical activity (SQUASH) [87]	11 items, organized into 4 different physical activities measuring frequency, duration and intensity (physical activity to and from home, household activities, activities at work and physical activities performed during leisure time)	X	X	X	X	X
Tumor hypoxia and immune cell infiltration	Two tumor biopsies: from routine diagnostic investigation and from surgical tumor excision	Immunohistochemistry analysis will be performed for hypoxia and immune cell infiltration biomarkers using the	X		X		

		laboratory of the Karolinska Institutet (Sweden) and their according protocols						
Cost-effectiveness	EuroQol 5-dimension (EQ-5D-5L) [88]	5 items (dimensions) multi-attribute utility questionnaire that measures mobility, self-care, usual activities, pain/discomfort and anxiety/depression in 5 levels	X	X	X	X	X	X
	iMTA medical consumption questionnaire (iMCQ) [89] and productivity costs questionnaire (iPCQ) [90]	Patient reported productivity losses and medical consumption		X	X	X	X	X
	Health care costs	Medical activities abstracted from the management systems of the hospitals						X
<b>Other outcomes</b>								
Sociodemographic and clinical data	Sociodemographic data, disease, and treatment characteristics will be abstracted from medical records or reported by the patient	Patient reported: place of birth, sex, marital status, living and work situation, education, lifestyle variables, and the self-administrated comorbidity questionnaire [91]  Medical records: birth month and year, date of diagnosis, date and type of treatment, tumor characteristics, ASA score, WHO score  Patient reported: smoking status	X					
			X	X	X	X	X	X
Coping mechanism	Sense of coherence questionnaire [92]	13 items, categorized into three scales: comprehensibility, manageability, meaningfulness	X					
Compliance to the intervention	Adherence rates	Patient reported: self-composed (activity) diary  Physical therapist: adherence of the physical exercise training intervention on standardized training session forms	X	X	X			
Patient evaluation	Self-composed questionnaire	Patients in the intervention group: satisfaction with the program and willingness to participate in focus group  Patients in the control group: evaluate contamination  Both groups: evaluation of possible post-surgical intervention						X
Non-participation	Self-composed questionnaire	Patient reported outcomes: sociodemographic, health- and bladder cancer-related quality of life, anxiety and depression, fatigue, physical activity, coping mechanism, and reason(s) for not participating  Medical records: birth month and year, date of diagnosis, date and type of treatment, tumor characteristics, ASA score, WHO score	X					

Table 2. Content of the supervised physical exercise training program in the intervention group

Frequency	Intensity	Time	Type
Three times a week	Aerobic interval training, consisting of 4 intervals of alternating effort performed on a cycle ergometer: - 4 min of low-intensity exercise, defined as 30% of the workload achieved at VO <sub>2</sub> peak - 2-3 min of high-intensity exercise, defined as 90% of the workload achieved at VO <sub>2</sub> peak <sup>a</sup>	24-28 min	Aerobic interval training
Two times a week	During neoadjuvant treatment: <b>Week 1 – 3:</b> consisting of 20 minutes on a cycle ergometer and 10 minutes on a different aerobic machine, corresponding to 30% of the heart rate reserve <b>Week 4 – 6:</b> consisting of 20 minutes on a cycle ergometer and 10 minutes on a different aerobic machine, corresponding to 40% of the heart rate reserve <b>Week 7 – 9:</b> consisting of 20 minutes on a cycle ergometer and 10 minutes on a different aerobic machine, corresponding to 50% of the heart rate reserve <b>Week 10 – 12 (and further):</b> consisting of 20 minutes on a cycle ergometer and 10 minutes on a different aerobic machine, corresponding to 60% of the heart rate reserve	30 min	Aerobic training
Two times a week	Resistance training, consisting of training six large muscle groups (leg press, bench press or chest press, abdominal crunch, pull over, low row, and step up) <sup>b</sup> in 2 sets: - Week 1: maximal 15 repetitions at ~65% of 1RM per set - Week 2: maximal 12 repetitions at ~70% of 1RM per set (weight week 1 +10%) - Week 3: maximal 10 repetitions at ~75% of 1RM per set (weight week 2 +10%) - From week 4 maximal 10 repetitions per set <sup>c</sup>	~20 min	Resistance training
Once a week	Progressive muscle relaxation techniques [35]	~20 min	Relaxation exercises

Abbreviations: 1RM=one-repetition maximum; CPET=cardiopulmonary exercise test; VO<sub>2</sub>peak=oxygen uptake at peak exercise.

<sup>a</sup> Further tailoring is done by the physical therapists: if a patient is not able to complete the high-intensity interval, the intensity will be reduced by 10%. The intensity can be reduced further in steps of 10% until the patient can complete all four high-intensity intervals. If a patient is able to complete all high-intensity intervals, moderate and high intensity will be increased by 10% [93]. During neoadjuvant treatment [94]: if a patient scores below a Borg score of 12 intensity is increased, if a patient scores above a Borg score of 15 intensity is decreased.

<sup>b</sup> Physical therapists can offer alternative resistance exercises targeting the same muscle group to accommodate a patient's abilities and preferences.

<sup>c</sup> If the patient is able to do two repetitions more than planned, the load will be increased by 10%. The load will be decreased by 10% if the patient is not able to achieve the planned number of repetitions.



Table 3. The Clavien-Dindo classification of surgical complications

Grade	Definition
Grade I	Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic and radiological interventions Allowed therapeutic regimens are: drugs as antiemetics, antipyretics, analgetics, diuretics and electrolytes and physical therapy This grade also includes wound infections opened at the bedside
Grade II	Requiring pharmacological treatment with drugs other than such allowed for grade I complications Blood transfusions and total parenteral nutrition are also included
Grade III	Requiring surgical, endoscopic, or radiological intervention
-IIIa	Intervention not under general anesthesia
-IIIb	Intervention under general anesthesia
Grade IV	Life-threatening complication (including CNS complications) <sup>a</sup> requiring IC/ICU-management
-IVa	Single organ dysfunction (including dialysis)
-IVb	Multiorgan dysfunction
Grade V	Death of a patient

Adapted from [39].

Abbreviations: CNS=central nervous system; IC=intermediate care; ICU=intensive care unit.

<sup>a</sup> brain hemorrhage, ischemic stroke, subarachnoidal bleeding, but excluding transient ischemic attacks (TIA)

1. Sung, H., et al., *Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries*. CA: a cancer journal for clinicians, 2021. **71**(3): p. 209-249.
2. Stein, J.P. and D.G. Skinner, *Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure*. World journal of urology, 2006. **24**(3): p. 296-304.
3. Witjes, J.A., et al., *Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer*. European urology, 2017. **71**(3): p. 462-475.
4. Babjuk, M., et al., *European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)*. European urology, 2021.
5. Maibom, S.L., et al., *Short-term morbidity and mortality following radical cystectomy: a systematic review*. BMJ open, 2021. **11**(4): p. e043266.
6. Shabsigh, A., et al., *Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology*. European urology, 2009. **55**(1): p. 164-176.
7. Novara, G., et al., *Complications and mortality after radical cystectomy for bladder transitional cell cancer*. The Journal of urology, 2009. **182**(3): p. 914-921.
8. Bochner, B.H., D.D. Sjoberg, and V.P. Laudone, *A randomized trial of robot-assisted laparoscopic radical cystectomy*. New England journal of medicine, 2014. **371**(4): p. 389-390.
9. Prentis, J.M., et al., *Impaired cardiopulmonary reserve in an elderly population is related to postoperative morbidity and length of hospital stay after radical cystectomy*. BJU international, 2013. **112**(2): p. E13-E19.
10. Tolchard, S., et al., *Cardiopulmonary reserve as determined by cardiopulmonary exercise testing correlates with length of stay and predicts complications after radical cystectomy*. BJU international, 2015. **115**(4): p. 554-561.
11. Arora, K., et al., *Early complications and mortality following radical cystectomy: associations with malnutrition and obesity*. Bladder Cancer, 2018. **4**(4): p. 377-388.
12. Mavros, M.N., et al., *Do psychological variables affect early surgical recovery?* PloS one, 2011. **6**(5): p. e20306.
13. Sathianathen, N.J., et al., *Increased surgical complications in smokers undergoing radical cystectomy*. Bladder Cancer, 2018. **4**(4): p. 403-409.
14. Jack, S., et al., *The effect of neoadjuvant chemotherapy on physical fitness and survival in patients undergoing oesophagogastric cancer surgery*. European Journal of Surgical Oncology (EJSO), 2014. **40**(10): p. 1313-1320.
15. West, M., et al., *Cardiopulmonary exercise testing for the prediction of morbidity risk after rectal cancer surgery*. Journal of British Surgery, 2014. **101**(9): p. 1166-1172.
16. Sinclair, R., et al., *The impact of neoadjuvant chemotherapy on cardiopulmonary physical fitness in gastro-oesophageal adenocarcinoma*. The Annals of The Royal College of Surgeons of England, 2016. **98**(6): p. 396-400.
17. Thomson, I.G., et al., *Neoadjuvant therapy reduces cardiopulmonary function in patients undergoing oesophagectomy*. International Journal of Surgery, 2018. **53**: p. 86-92.
18. Jensen, B.T., et al., *Efficacy of a multiprofessional rehabilitation programme in radical cystectomy pathways: a prospective randomized controlled trial*. Scandinavian journal of urology, 2015. **49**(2): p. 133-141.
19. Minnella, E.M., et al., *Multimodal prehabilitation to enhance functional capacity following radical cystectomy: a randomized controlled trial*. European Urology Focus, 2021. **7**(1): p. 132-138.
20. Banerjee, S., et al., *Vigorous intensity aerobic interval exercise in bladder cancer patients prior to radical cystectomy: a feasibility randomised controlled trial*. Supportive Care in Cancer, 2018. **26**(5): p. 1515-1523.


- 1
- 2
- 3
- 4 21. Kaye, D.R., et al., *The feasibility and impact of a Presurgical exercise intervention program (Prehabilitation) for patients undergoing cystectomy for bladder cancer*. *Urology*, 2020. **145**: p. 106-112.
- 5
- 6
- 7 22. Jensen, B.T., et al., *Exercise-based pre-habilitation is feasible and effective in radical cystectomy pathways—secondary results from a randomized controlled trial*. *Supportive Care in Cancer*, 2016. **24**(8): p. 3325-3331.
- 8
- 9
- 10 23. Thomas, G., et al., *Prehabilitation before major intra-abdominal cancer surgery: a systematic review of randomised controlled trials*. *European journal of anaesthesiology*, 2019. **36**(12): p. 933.
- 11
- 12
- 13 24. Wiggins, J.M., et al., *Exercise and the tumor microenvironment: potential therapeutic implications*. *Exercise and sport sciences reviews*, 2018. **46**(1): p. 56-64.
- 14
- 15 25. Zhang, X., et al., *Can Exercise-Induced Modulation of the Tumor Physiologic Microenvironment Improve Antitumor Immunity? Exercise, Immunity, and Physiologic Microenvironment*. *Cancer research*, 2019. **79**(10): p. 2447-2456.
- 16
- 17 26. Shannon, A.M., et al., *Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies*. *Cancer treatment reviews*, 2003. **29**(4): p. 297-307.
- 18
- 19 27. Peixoto, A., et al., *Hypoxia enhances the malignant nature of bladder cancer cells and concomitantly antagonizes protein O-glycosylation extension*. *Oncotarget*, 2016. **7**(39): p. 63138.
- 20
- 21 28. Boström, P., et al., *Hypoxia marker GLUT-1 (glucose transporter 1) is an independent prognostic factor for survival in bladder cancer patients treated with radical cystectomy*. *Bladder Cancer*, 2016. **2**(1): p. 101-109.
- 22
- 23 29. Pocock, S.J. and R. Simon, *Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial*. *Biometrics*, 1975: p. 103-115.
- 24
- 25 30. Jin, M., A. Polis, and J. Hartzel. *R package 'Minirand'. 0.1.3. ed. CRAN*. 2020; Available from: <https://cran.r-project.org/web/packages/Minirand/Minirand.pdf>.
- 26
- 27 31. Jin, M., A. Polis, and J. Hartzel, *Algorithms for minimization randomization and the implementation with an R package*. *Communications in Statistics-Simulation and Computation*, 2021. **50**(10): p. 3077-3087.
- 28
- 29 32. Campbell, K.L., et al., *Exercise guidelines for cancer survivors: consensus statement from international multidisciplinary roundtable*. *Medicine and science in sports and exercise*, 2019. **51**(11): p. 2375.
- 30
- 31 33. Rock, C.L., et al., *American Cancer Society nutrition and physical activity guideline for cancer survivors*. *CA: A Cancer Journal for Clinicians*, 2022. **72**(3): p. 230-262.
- 32
- 33 34. Cerantola, Y., et al., *Guidelines for perioperative care after radical cystectomy for bladder cancer: Enhanced Recovery After Surgery (ERAS®) society recommendations*. *Clinical nutrition*, 2013. **32**(6): p. 879-887.
- 34
- 35 35. Jacobson, E., *You must relax*. 1934.
- 36
- 37 36. Cermak, N.M., et al., *Protein supplementation augments the adaptive response of skeletal muscle to resistance-type exercise training: a meta-analysis*. *The American journal of clinical nutrition*, 2012. **96**(6): p. 1454-1464.
- 38
- 39 37. Zigmond, A.S. and R.P. Snaith, *The hospital anxiety and depression scale*. *Acta psychiatrica scandinavica*, 1983. **67**(6): p. 361-370.
- 40
- 41 38. Antonovsky, H. and S. Sagy, *The development of a sense of coherence and its impact on responses to stress situations*. *Journal of Social Psychology*, 1986. **126**(2): p. 213-226.
- 42
- 43 39. Dindo, D., N. Demartines, and P.-A. Clavien, *Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey*. *Annals of surgery*, 2004. **240**(2): p. 205.
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
- 2
- 3
- 4 40. Berkel, A.E., et al., *The effects of prehabilitation versus usual care to reduce postoperative complications in high-risk patients with colorectal cancer or dysplasia scheduled for elective colorectal resection: study protocol of a randomized controlled trial*. BMC gastroenterology, 2018. **18**(1): p. 1-14.
- 5
- 6
- 7
- 8 41. Dronkers, J., et al., *Prevention of pulmonary complications after upper abdominal surgery by preoperative intensive inspiratory muscle training: a randomized controlled pilot study*. Clinical rehabilitation, 2008. **22**(2): p. 134-142.
- 9
- 10
- 11 42. Dronkers, J., et al., *Preoperative therapeutic programme for elderly patients scheduled for elective abdominal oncological surgery: a randomized controlled pilot study*. Clinical rehabilitation, 2010. **24**(7): p. 614-622.
- 12
- 13
- 14 43. Kulkarni, S., et al., *Pre-operative inspiratory muscle training preserves postoperative inspiratory muscle strength following major abdominal surgery—a randomised pilot study*. The Annals of The Royal College of Surgeons of England, 2010. **92**(8): p. 700-705.
- 15
- 16 44. Barbalho-Moulim, M.C., et al., *Effects of preoperative inspiratory muscle training in obese women undergoing open bariatric surgery: respiratory muscle strength, lung volumes, and diaphragmatic excursion*. Clinics, 2011. **66**(10): p. 1721-1727.
- 17
- 18 45. Soares, S.M.d.T.P., et al., *Pulmonary function and physical performance outcomes with preoperative physical therapy in upper abdominal surgery: a randomized controlled trial*. Clinical rehabilitation, 2013. **27**(7): p. 616-627.
- 19
- 20 46. van Adrichem, E.J., et al., *Comparison of two preoperative inspiratory muscle training programs to prevent pulmonary complications in patients undergoing esophagectomy: a randomized controlled pilot study*. Annals of surgical oncology, 2014. **21**(7): p. 2353-2360.
- 21
- 22 47. Halliday, L.J., et al., *The impact of prehabilitation on post-operative outcomes in oesophageal cancer surgery: a propensity score matched comparison*. Journal of Gastrointestinal Surgery, 2021. **25**(11): p. 2733-2741.
- 23
- 24 48. Low, D.E., et al., *Benchmarking complications associated with esophagectomy*. Annals of surgery, 2019. **269**(2): p. 291-298.
- 25
- 26 49. Wijnburg, C.J., et al., *Robot-assisted radical cystectomy versus open radical cystectomy in bladder cancer patients: a multicentre comparative effectiveness study*. European Urology, 2021. **79**(5): p. 609-618.
- 27
- 28 50. Barberan-Garcia, A., et al., *Personalised prehabilitation in high-risk patients undergoing elective major abdominal surgery: a randomized blinded controlled trial*. 2018, LWW.
- 29
- 30 51. Berkel, A.E., et al., *Effects of community-based exercise prehabilitation for patients scheduled for colorectal surgery with high risk for postoperative complications: results of a randomized clinical trial*. Annals of surgery, 2022. **275**(2): p. e299.
- 31
- 32 52. Zou, G., *A modified poisson regression approach to prospective studies with binary data*. American journal of epidemiology, 2004. **159**(7): p. 702-706.
- 33
- 34 53. Cohen, J., *Statistical power analysis for the behavioral sciences*. 2013: Routledge.
- 35
- 36 54. Briggs, A., M. Sculpher, and K. Claxton, *Decision modelling for health economic evaluation*. 2006: Oup Oxford.
- 37
- 38 55. Vallejo-Torres, L., et al., *Integrating health economics modeling in the product development cycle of medical devices: a Bayesian approach*. International journal of technology assessment in health care, 2008. **24**(4): p. 459-464.
- 39
- 40 56. Hakkaart-van Roijen, L., S. Tan, and C. Bouwmans, *Manual for Cost Research: methods and standard cost prices for economic evaluations in health care*. Diemen: Health Care Insurance Board, 2010.
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1  
2  
3 57. Mauskopf, J.A., et al., *Principles of good practice for budget impact analysis: report of the ISPOR*  
4 *Task Force on good research practices—budget impact analysis*. Value in health, 2007. **10**(5): p.  
5 336-347.
- 6 58. Gregg, J.R., et al., *Effect of preoperative nutritional deficiency on mortality after radical*  
7 *cystectomy for bladder cancer*. The Journal of urology, 2011. **185**(1): p. 90-96.
- 8 59. Barbosa, A.L., et al., *Smoking intensity and bladder cancer aggressiveness at diagnosis*. PLoS  
9 One, 2018. **13**(3): p. e0194039.
- 10 60. Bellg, A.J., et al., *Enhancing treatment fidelity in health behavior change studies: best practices*  
11 *and recommendations from the NIH Behavior Change Consortium*. Health psychology, 2004.  
12 **23**(5): p. 443.
- 13 61. van Waart, H., et al., *Why do patients choose (not) to participate in an exercise trial during*  
14 *adjuvant chemotherapy for breast cancer?* Psycho-Oncology, 2016. **25**(8): p. 964-970.
- 15 62. Vd Wiel, H.J., et al., *Characteristics of participants and nonparticipants in a blended internet-*  
16 *based physical activity trial for breast and prostate cancer survivors: Cross-sectional study*. JMIR  
17 cancer, 2021. **7**(4): p. e25464.
- 18 63. Agasi-Idenburg, C.S., et al., *"I am busy surviving"—Views about physical exercise in older adults*  
19 *scheduled for colorectal cancer surgery*. Journal of geriatric oncology, 2020. **11**(3): p. 444-450.
- 20 64. Ormel, H., et al., *Predictors of adherence to exercise interventions during and after cancer*  
21 *treatment: a systematic review*. Psycho-oncology, 2018. **27**(3): p. 713-724.
- 22 65. Banerjee, S., et al., *Patient perspectives of vigorous intensity aerobic interval exercise*  
23 *prehabilitation prior to radical cystectomy: a qualitative focus group study*. Disability and  
24 rehabilitation, 2021. **43**(8): p. 1084-1091.
- 25 66. van Wijk, L., et al., *Improved preoperative aerobic fitness following a home-based bimodal*  
26 *prehabilitation programme in high-risk patients scheduled for liver or pancreatic resection*.  
27 British Journal of Surgery, 2022. **109**(11): p. 1036-1039.
- 28 67. Krajewski, W., et al., *How to lower postoperative complications after radical cystectomy—a*  
29 *review*. Central European journal of urology, 2016. **69**(4): p. 370.
- 30 68. Mewes, J.C., et al., *Effectiveness of multidimensional cancer survivor rehabilitation and cost-*  
31 *effectiveness of cancer rehabilitation in general: a systematic review*. The oncologist, 2012.  
32 **17**(12): p. 1581-1593.
- 33 69. Lukez, A. and J. Baima. *The role and scope of prehabilitation in cancer care*. in *Seminars in*  
34 *oncology nursing*. 2020. Elsevier.
- 35 70. Moore, S.C., et al., *Association of leisure-time physical activity with risk of 26 types of cancer in*  
36 *1.44 million adults*. JAMA internal medicine, 2016. **176**(6): p. 816-825.
- 37 71. Friedenreich, C.M., et al., *Physical Activity and Cancer Outcomes: A Precision Medicine*  
38 *Approach* *Physical Activity and Cancer: A Precision Medicine Approach*. Clinical Cancer Research,  
39 2016. **22**(19): p. 4766-4775.
- 40 72. Petrova, V., et al., *The hypoxic tumour microenvironment*. Oncogenesis, 2018. **7**(1): p. 1-13.
- 41 73. Theodoropoulos, V.E., et al., *Hypoxia-inducible factor 1 $\alpha$  expression correlates with angiogenesis*  
42 *and unfavorable prognosis in bladder cancer*. European urology, 2004. **46**(2): p. 200-208.
- 43 74. Koelwyn, G.J., et al., *Exercise-dependent regulation of the tumour microenvironment*. Nature  
44 Reviews Cancer, 2017. **17**(10): p. 620-632.
- 45 75. Jones, L.W., et al., *Effect of aerobic exercise on tumor physiology in an animal model of human*  
46 *breast cancer*. Journal of applied physiology, 2010. **108**(2): p. 343-348.
- 47 76. McCullough, D.J., et al., *Effects of exercise training on tumor hypoxia and vascular function in the*  
48 *rodent preclinical orthotopic prostate cancer model*. Journal of applied physiology, 2013.  
49 **115**(12): p. 1846-1854.
- 50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 77. Betof, A.S., et al., *Modulation of murine breast tumor vascularity, hypoxia, and*  
4 *chemotherapeutic response by exercise*. JNCI: Journal of the National Cancer Institute, 2015.  
5 **107**(5).
- 6 78. Schumacher, O., et al., *Exercise modulation of tumour perfusion and hypoxia to improve*  
7 *radiotherapy response in prostate cancer*. Prostate Cancer and Prostatic Diseases, 2021. **24**(1): p.  
8 1-14.
- 9 79. Seet-Lee, C., et al., *The effect of aerobic exercise on tumour blood delivery: a systematic review*  
10 *and meta-analysis*. Supportive Care in Cancer, 2022: p. 1-17.
- 11 80. Guralnik, J.M., et al., *A short physical performance battery assessing lower extremity function:*  
12 *association with self-reported disability and prediction of mortality and nursing home admission*.  
13 Journal of gerontology, 1994. **49**(2): p. M85-M94.
- 14 81. Langius, J., et al., *Meetprotocol handknijpkracht mbv Hand Dynamometer*. Nutritional  
15 Assessment Platform, 2016.
- 16 82. McAllister, L.S. and K.M. Palombaro, *Modified 30-second sit-to-stand test: reliability and validity*  
17 *in older adults unable to complete traditional sit-to-stand testing*. Journal of Geriatric Physical  
18 Therapy, 2020. **43**(3): p. 153-158.
- 19 83. Bauer, J., S. Capra, and M. Ferguson, *Use of the scored Patient-Generated Subjective Global*  
20 *Assessment (PG-SGA) as a nutrition assessment tool in patients with cancer*. European journal of  
21 clinical nutrition, 2002. **56**(8): p. 779-785.
- 22 84. Aaronson, N.K., et al., *The European Organization for Research and Treatment of Cancer QLQ-*  
23 *C30: a quality-of-life instrument for use in international clinical trials in oncology*. JNCI: Journal of  
24 the National Cancer Institute, 1993. **85**(5): p. 365-376.
- 25 85. Danna, B.J., et al., *Assessing symptom burden in bladder cancer: an overview of bladder cancer*  
26 *specific health-related quality of life instruments*. Bladder cancer, 2016. **2**(3): p. 329-340.
- 27 86. Smets, E., et al., *The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an*  
28 *instrument to assess fatigue*. Journal of psychosomatic research, 1995. **39**(3): p. 315-325.
- 29 87. Wendel-Vos, G.W., et al., *Reproducibility and relative validity of the short questionnaire to assess*  
30 *health-enhancing physical activity*. Journal of clinical epidemiology, 2003. **56**(12): p. 1163-1169.
- 31 88. Uyl-de Groot, C.A., F.F. Rutten, and G.J. Bonsel, *Measurement and valuation of quality of life in*  
32 *economic appraisal of cancer treatment*. European Journal of Cancer, 1994. **30**(1): p. 111-117.
- 33 89. Bouwmans, C., et al., *Medical cost questionnaire (iMCQ)*. Rotterdam: iMTA, Erasmus Universiteit  
34 Rotterdam, 2013.
- 35 90. Bouwmans, C., et al., *Productivity Cost Questionnaire*. Erasmus University Rotterdam: Institute  
36 for Medical Technology Assesment, 2013.
- 37 91. Sangha, O., et al., *The Self-Administered Comorbidity Questionnaire: a new method to assess*  
38 *comorbidity for clinical and health services research*. Arthritis Care & Research: Official Journal of  
39 the American College of Rheumatology, 2003. **49**(2): p. 156-163.
- 40 92. Antonovsky, A., *The structure and properties of the sense of coherence scale*. Social science &  
41 medicine, 1993. **36**(6): p. 725-733.
- 42 93. van Rooijen, S., et al., *Multimodal prehabilitation in colorectal cancer patients to improve*  
43 *functional capacity and reduce postoperative complications: the first international randomized*  
44 *controlled trial for multimodal prehabilitation*. BMC cancer, 2019. **19**(1): p. 1-11.
- 45 94. Swain, D.P., C.A. Brawner, and A.C.o.S. Medicine, *ACSM's resource manual for guidelines for*  
46 *exercise testing and prescription*. 2014: Wolters Kluwer Health/Lippincott Williams & Wilkins.
- 47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 1. Study flow chart





SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	3, 7
	2b	All items from the World Health Organization Trial Registration Data Set	3, 7
Protocol version	3	Date and version identifier	N.A.
Funding	4	Sources and types of financial, material, and other support	17
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1, 2, 17
	5b	Name and contact information for the trial sponsor	17
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	17
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	7



1 **Introduction**

2

3 Background and 6a Description of research question and justification for undertaking the trial, including summary of relevant 5, 6

4 rationale studies (published and unpublished) examining benefits and harms for each intervention

5

6 6b Explanation for choice of comparators 8

7

8 Objectives 7 Specific objectives or hypotheses 6

9

10 Trial design 8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), 7

11 allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)

12

13

14 **Methods: Participants, interventions, and outcomes**

15

16 Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will 7

17 be collected. Reference to where list of study sites can be obtained

18

19 Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and 7

20 individuals who will perform the interventions (eg, surgeons, psychotherapists)

21

22

23 Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and when they will be 8-10, Table 2

24 administered

25

26 11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose 11

27 change in response to harms, participant request, or improving/worsening disease)

28

29 11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence 10,11, 14

30 (eg, drug tablet return, laboratory tests)

31

32 11d Relevant concomitant care and interventions that are permitted or prohibited during the trial 8

33

34 Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood 10, 11

35 pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen

36 efficacy and harm outcomes is strongly recommended

37

38

39

40 Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for 7, 8, Figure 1, Table 1

41 participants. A schematic diagram is highly recommended (see Figure)

42

43

44

45

46

1	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	<u>11</u>
2				
3				
4	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	<u>11</u>
5				

### 7 **Methods: Assignment of interventions (for controlled trials)**

#### 8 Allocation:

10	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	<u>7</u>
11				
12				
13				
14				
15				
16	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	<u>7</u>
17				
18				
19				
20				
21	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	<u>7</u>
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	<u>7</u>
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	<u>N.A.</u>
28				
29				
30				

### 31 **Methods: Data collection, management, and analysis**

33	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	<u>10, 11, Table 1</u>
34				
35				
36				
37				
38				
39		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	<u>Table 2</u>
40				
41				
42				

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	<u>10</u>
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	<u>11-13</u>
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	<u>12, 13</u>
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	<u>12</u>
11				
12				
13				
14	<b>Methods: Monitoring</b>			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	<u>10</u>
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	<u>N.A.</u>
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	<u>8, 14</u>
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	<u>N.A.</u>
29				
30				
31				
32	<b>Ethics and dissemination</b>			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	<u>7</u>
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	<u>13</u>
38				
39				
40				
41				
42				
43				
44				
45				
46				

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	7
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	7
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	10
8				
9				
10	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	17
11				
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	10
14				
15				
16	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	N.A.
17				
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	3
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	N.A.
25				
26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	N.A.
27				
28				
29	<b>Appendices</b>			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	N.A.
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	N.A.
35				
36				

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.

# BMJ Open

## Effectiveness of a multimodal prehabilitation program in patients with bladder cancer undergoing radical cystectomy: protocol of the ENHANCE multicenter randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-071304.R1
Article Type:	Protocol
Date Submitted by the Author:	13-Feb-2023
Complete List of Authors:	<p>Akdemir, Emine; Netherlands Cancer Institute, Division of Psychosocial Research and Epidemiology; Netherlands Cancer Institute, Center for Quality of Life</p> <p>Sweegers, Maïke; Netherlands Cancer Institute, Division of Psychosocial Research and Epidemiology; Netherlands Cancer Institute, Center for Quality of Life</p> <p>Vrieling, Alina; Radboudumc, Department for Health Evidence</p> <p>Rundqvist, Helene; Karolinska Institutet, Department of Laboratory Medicine</p> <p>Meijer, Richard; University Medical Centre Utrecht, Department of Oncological Urology</p> <p>Leliveld-Kors, Annemarie; University Medical Centre Groningen, Department of Urology</p> <p>van der Heijden, Toine; Radboudumc, Department of Urology</p> <p>Rutten, Vera; Erasmus MC, Department of Urology, Erasmus MC Cancer Institute</p> <p>Koldewijn, Evert; Catharina Hospital, Department of Urology</p> <p>Bos, Siebe; Noordwest Ziekenhuisgroep, Department of Urology</p> <p>Wijburg, Carl; Rijnstate Hospital, Department of Urology</p> <p>Marcelissen, Tom; Maastricht University Medical Centre+, Department of Urology</p> <p>Bongers, Bart; Maastricht University, Department of Nutrition and Movement Sciences, Nutrition and Translational Research in Metabolism (NUTRIM), Faculty of Health, Medicine and Life Sciences; Maastricht University, Department of Surgery, Nutrition and Translational Research in Metabolism (NUTRIM), Faculty of Health, Medicine and Life Sciences</p> <p>Retèl, Valesca; Netherlands Cancer Institute, Division of Psychosocial Research and Epidemiology; Erasmus University Rotterdam, Erasmus School of Health Policy and Management</p> <p>Van Harten, Wim; Netherlands Cancer Institute, Division of Psychosocial Research and Epidemiology; University of Twente, Department of Health Technology Services Research</p> <p>May, Anne; University Medical Centre Utrecht, Julius Center for Health Sciences and Primary Care</p> <p>Groen, Wim; Netherlands Cancer Institute, Division of Psychosocial Research and Epidemiology; Amsterdam UMC Locatie VUmc, Department of Medicine for Older People, Amsterdam Public Health &amp; Amsterdam Movement Sciences</p>

	Stuiver, Martijn; Netherlands Cancer Institute, Division of Psychosocial Research and Epidemiology; Amsterdam University of Applied Sciences, Centre of Expertise Urban Vitality, Faculty of Health
<b>Primary Subject Heading</b>:	Oncology
Secondary Subject Heading:	Surgery, Rehabilitation medicine
Keywords:	Urological tumours < ONCOLOGY, REHABILITATION MEDICINE, Nutritional support < ONCOLOGY, SURGERY

SCHOLARONE™  
Manuscripts

**TITLE PAGE****Title**

EffectiveNess of a multimodal preHAbilitation program in patieNts with bladder canCER undergoing radical cystectomy: protocol of the ENHANCE multicenter randomized controlled trial

**Authors and affiliations**

Emine Akdemir<sup>1,2</sup>, Maïke G. Sweegers<sup>1,2</sup>, Alina Vrieling<sup>3</sup>, Helene Rundqvist<sup>4</sup>, Richard P. Meijer<sup>5</sup>, Annemarie M. Leliveld-Kors<sup>6</sup>, Antoine G. van der Heijden<sup>7</sup>, Vera P. Rutten<sup>8</sup>, Evert L. Koldewijn<sup>9</sup>, Siebe D. Bos<sup>10</sup>, Carl J. Wijburg<sup>11</sup>, Tom A.T. Marcelissen<sup>12</sup>, Bart C. Bongers<sup>13,14</sup>, Valesca P. Retel<sup>1,15</sup>, Wim. H. van Harten<sup>1,16</sup>, Anne M. May<sup>17</sup>, Wim G. Groen<sup>1,18</sup> \*, Martijn M. Stuiver<sup>1,2,19</sup>

Correspondence to dr. Martijn M. Stuiver; [m.stuiver@nki.nl](mailto:m.stuiver@nki.nl)

<sup>1</sup> Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

<sup>2</sup> Center for Quality of Life, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

<sup>3</sup> Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands

<sup>4</sup> Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden

<sup>5</sup> Department of Oncological Urology, University Medical Center Utrecht, Utrecht, The Netherlands

<sup>6</sup> Department of Urology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands

<sup>7</sup> Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands

<sup>8</sup> Department of Urology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands

<sup>9</sup> Department of Urology, Catharina Hospital, Eindhoven, The Netherlands

<sup>10</sup> Department of Urology, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands

<sup>11</sup> Department of Urology, Rijnstate Hospital, Arnhem, The Netherlands

<sup>12</sup> Department of Urology, Maastricht University Medical Centre+, Maastricht, The Netherlands

<sup>13</sup> Department of Nutrition and Movement Sciences, Nutrition and Translational Research in Metabolism (NUTRIM), Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands

<sup>14</sup> Department of Surgery, Nutrition and Translational Research in Metabolism (NUTRIM), Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands

<sup>15</sup> Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands

<sup>16</sup> Department of Health Technology and Services Research, University of Twente, Enschede, The Netherlands

1  
2  
3 <sup>17</sup> Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht,  
4 The Netherlands

5  
6 <sup>18</sup> Department of Medicine for older people, Amsterdam UMC, Amsterdam Public Health & Amsterdam Movement  
7 Sciences, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands

8  
9 <sup>19</sup> Centre of Expertise Urban Vitality, Faculty of Health, Amsterdam University of Applied Sciences, Amsterdam, The  
10 Netherlands

11  
12 \* MMS and WG contributed to this work equally, shared last author.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



## ABSTRACT

**Introduction** Radical cystectomy (RC) is the standard treatment for patients with non-metastatic muscle-invasive bladder cancer, as well as for patients with therapy refractory high-risk non-muscle invasive bladder cancer. However, 50-65% of patients undergoing RC experience perioperative complications. The risk, severity, and impact of these complications is associated with a patient's preoperative cardiorespiratory fitness, nutritional and smoking status, and presence of anxiety and depression. There is emerging evidence supporting multimodal prehabilitation as a strategy to reduce the risk of complications and improve functional recovery after major cancer surgery. However, for bladder cancer the evidence is still limited. The aim of this study is to investigate the superiority of a multimodal prehabilitation program versus standard-of-care in terms of reducing perioperative complications in patients with bladder cancer undergoing RC.

**Methods and analysis** This multicenter, open label, prospective, randomized controlled trial, will include 154 patients with bladder cancer undergoing RC. Patients are recruited from eight hospitals in The Netherlands and will be randomly (1:1) allocated to the intervention group receiving a structured multimodal prehabilitation program of approximately 3-6 weeks, or to the control group receiving standard-of-care. The primary outcome is the proportion of patients who develop one or more grade  $\geq 2$  complications (according to the Clavien-Dindo classification) within 90 days of surgery. Secondary outcomes include cardiorespiratory fitness, length of hospital stay, health-related quality of life, tumor tissue biomarkers of hypoxia, immune cell infiltration, and cost-effectiveness. Data collection will take place at baseline, before surgery, and 4 and 12 weeks after surgery.

**Ethics and dissemination** Ethical approval for this study was granted by the Medical Ethics Committee NedMec (Amsterdam, The Netherlands) under reference number 22-595/NL78792.031.22. Results of the study will be published in international peer-reviewed journals.

**Trial registration number** Clinical Trials (NCT05480735). Prospectively registered on 29 July 2022.

**STRENGTHS AND LIMITATIONS OF THIS STUDY**

- This is a multicenter randomized controlled trial investigating the effects of multimodal prehabilitation in an understudied group of patients with bladder cancer undergoing radical cystectomy.
- This data collected in this study enables exploration of the effects of prehabilitation on tumor hypoxia and immune cell infiltration.
- The intervention accounts for heterogeneity in cancer treatment by offering additional support during neoadjuvant treatment when appropriate.
- This study includes a cost-effectiveness analysis from a societal perspective.
- Due to the two-group design and the multimodal intervention, it will not be possible to disentangle the independent effects of physical exercise training, nutritional support, psychological counseling, and smoking cessation.

## INTRODUCTION

Bladder cancer is the 10<sup>th</sup> most common diagnosed cancer worldwide, with over 573,000 new patients and 213,000 deaths each year [1]. Radical cystectomy (RC) is the standard treatment for patients with non-metastatic muscle-invasive bladder cancer [2, 3], as well as for patients with therapy refractory high-risk non-muscle invasive bladder cancer [4]. RC is a challenging and costly surgical procedure with high morbidity and mortality rates [5]: 50-65% of the patients experience perioperative complications, of which 10-20% are high-grade [6-8]. Low cardiorespiratory fitness [9, 10], poor nutritional status [11], the presence of anxiety and depression [12], and smoking [13] increase the risk of perioperative complications, length of hospital stay, and the associated medical costs [9, 10]. In daily clinical practice, 25% of patients with muscle-invasive bladder cancer receive neoadjuvant treatment, which might further impair preoperative cardiorespiratory fitness and nutritional status [14-17].

Emerging evidence has identified the preoperative period as a window of opportunity to address lifestyle. Multimodal preoperative interventions, including physical exercise training, nutritional support, psychological counseling, and smoking cessation, that aim to increase a patient's tolerance to surgery, reduce the incidence, severity, and impact of complications, accelerate and improve the quality of recovery, and improve quality of life have been termed *prehabilitation*.

To date, no adequately powered trial has been performed to establish the effectiveness of a multimodal prehabilitation program for reducing the incidence, severity, and impact of complications and costs associated with RC for bladder cancer. A few studies investigated the impact of a single modal [18, 19] or multimodal [20, 21] prehabilitation program on functional recovery following RC. A phase I/II trial with 54 patients showed improvement in patient-reported quality of life after four weeks of a supervised physical exercise training program before surgery [19]. A feasibility randomized controlled trial with 60 patients provided evidence that a 3- to 6-week supervised vigorous aerobic exercise training program before surgery led to improvements in cardiorespiratory fitness parameters and possibly fewer surgical complications [18]. A randomized controlled trial with 107 patients demonstrated improvement in walking distance during seven days after surgery [20] and improved muscle power [22]. Finally, a randomized controlled trial with 70 patients showed significant better functional capacity in the intervention group that followed a multimodal program compared to the control group, at four weeks after surgery [21]. However, the physical exercise intervention in these studies including patients with bladder cancer had limitations with regard to therapeutic validity [23] due to a short duration of the

1  
2  
3 intervention [20, 22], relatively low exercise intensity [20-22], or only patient reported compliance with  
4 the exercise intervention [20-22].  
5

6  
7 Preclinical studies indicate that exercise may directly affect tumor characteristics such as normalization of  
8 tumor vasculature and immune cell infiltration, thereby enhancing tumor perfusion and reducing hypoxia  
9 [24, 25]. These factors are associated with treatment efficacy and survival [26-28]. The current study  
10 provides a unique opportunity to explore the effects of prehabilitation on tumor inflammation and  
11 hypoxia markers, which has not yet been studied in human patients.  
12  
13  
14

### 15 16 **Study objectives**

17 The ENHANCE study is designed to investigate the effectiveness of a multimodal prehabilitation program  
18 versus standard-of-care in patients approaching RC. The primary aim is to investigate the superiority of a  
19 multimodal prehabilitation program in terms of reducing one or more grade  $\geq 2$  perioperative  
20 complications within 90 days in patients with bladder cancer undergoing RC. Secondary outcomes include  
21 changes in preoperative cardiorespiratory fitness, length of hospital stay, health-related quality of life,  
22 tumor tissue biomarkers of hypoxia, immune cell infiltration, and cost-effectiveness.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## METHODS AND ANALYSIS

The ENHANCE study is a multicenter, open label, two-arm randomized controlled trial. Patient inclusion and data collection started in August 2022. Ethical approval, extending to all participating centers, was granted by the Medical Ethical Committee NedMec (Amsterdam, The Netherlands), under reference number 22-595/NL78792.031.22. The trial is prospectively registered in Clinical Trials (NCT05480735) on 29 July 2022.

### Study population

The study aims to include 154 patients who meet the following inclusion criteria: aged  $\geq 18$  years, histologically confirmed, primary, bladder cancer (cTa-4N0-3M0), and planned to undergo RC. Surgery will not be delayed in favor of prehabilitation. Hence, patients who are scheduled for surgery within 3 weeks are not eligible for the trial. Patients who express the intention to follow a similar exercise training program regardless of randomization outcome, patients with severe cognitive or psychiatric disorders, patients with a contraindication to perform physical exercise training or a cardiopulmonary exercise test (CPET), and patients unable to read or understand the Dutch language will also be excluded.

### Recruitment and randomization

Patients are recruited from eight academic or teaching hospitals across different regions in The Netherlands (Catharina Hospital, Erasmus Medical Center, Maastricht University Medical Center+, Noordwest Hospital Group, Radboud University Medical Center, Rijnstate Hospital, University Medical Center Groningen, and University Medical Center Utrecht). The Netherlands Cancer Institute is the coordinating center. After establishment of diagnosis and indication for surgery, the urologist or nurse specialist invites patients to participate in the study and provides the patient information letter. The study coordinator contacts these patients to provide further oral information and answer potential questions about the study. When a patient agrees to participate, written informed consent is obtained. After collection of baseline data, patients are randomized in a 1:1 ratio, using a minimization algorithm [29] aimed to achieve optimal balance between the two study arms with regard to the recruiting hospital, neoadjuvant treatment (yes/no), nodal status (N0/N1-3), and type of surgery (open/robot-assisted RC). Minimization is done using the Minirand package in R 4.0.4 [30, 31]. The algorithm includes a random component to ensure blinding of treatment allocation. Due to the nature of the intervention, blinding of participants and research investigators is not possible. After randomization, patients in both the intervention and control groups receive a leaflet with recommendations on physical activity, diet

and smoking cessation, according to the latest guidelines for patients with cancer [32, 33]. These recommendations are not further individualised or actively supported.

Patients who do not wish to participate in the study are asked to participate in a one-time questionnaire as described in Table 1. A participant flow diagram is shown in Figure 1.

Table 1. Outcome measures in the intervention and control group

Description of outcome	Assessment	Description of measure	T0a	T0b	T1	T2	T3
<b>Primary outcome</b>							
Proportion of patients who develop one or more grade $\geq 2$ perioperative complications within 90 days	Perioperative complications, Grade $\geq 2$ according to Clavien Dindo classification	Number of grade $\geq 2$ complication is abstracted from medical records				X	X
<b>Secondary outcomes</b>							
Proportion of patients who develop one or more high-grade ( $\geq 3$ ) complications, number of complications, length of hospital stay, and readmissions within 90 days	Perioperative complications, Grade $\geq 3$ according to Clavien Dindo classification, length of hospital stay, readmissions	Number of grade $\geq 3$ complications, number of complications, length of hospital stay in days, and readmissions abstracted from medical records				X	X
Cardiorespiratory fitness	Cardiopulmonary exercise test (CPET) on a cycle ergometer using a ramp protocol [34]	Peak oxygen uptake ( $VO_2$ peak in ml/kg/min)	X		X		
Physical functioning	Short physical performance battery (SPPB) [35]	5 items organized into three subscales of balance, walking speed, and lower extremity muscle strength	X		X		X
Upper extremity muscle strength	Handgrip strength using a handheld dynamometer [36]	The maximum score of three attempts of both hands in kilogram (kg)					
Lower extremity functional muscle strength	30-second sit-to-stand test [37]	The number of sit to stands within 30 seconds	X		X		X
Nutritional intake	24-h recall	Protein (total gram) and caloric intake (total kcal)	X		X		
Nutritional status	Patient-generated subjective global assessment short form (PG-SGA SF) [38]	4 items assessing weight (status), nutritional intake, symptoms, and physical functioning	X	X	X	X	X
	Nil per mouth consumption during hospitalization	The number of days after RC abstracted from medical records				X	X
Body composition	Bioelectrical impedance analysis	Body mass (kg), body height (cm), (subcutaneous) fat mass (%), and (upper limb) muscle mass (kg) are measured, and BMI ( $kg/m^2$ )	X		X		X
Health-related quality of life	EORTC quality of life questionnaire core 30 (QLQ-C30) [39]	30 items, organized into 5 functional scales (physical, role, emotional, cognitive, social), 3 symptom scales (pain, fatigue, and emesis), 6 items (dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial impact), and an overall QoL scale	X	X	X	X	X
Bladder cancer-related quality of life	EORTC muscle-invasive bladder cancer specific module (BLM-30) [40]	30 items, assessing urinary symptoms, bowel symptoms, sexual functioning, urostomy problems, difficulties associated with the use of a catheter and body image	X	X	X	X	X
Anxiety and depression	Hospital anxiety and depression scale (HADS) [41]	7 items assessing anxiety and 7 items assessing depression	X	X	X	X	X
Fatigue	Multidimensional fatigue inventory (MFI) [42]	20 items, categorized into five scales: general fatigue, physical fatigue, reduced activity, reduced motivation, and mental fatigue	X	X	X	X	X

Physical activity	Short questionnaire to assess health-enhancing physical activity (SQUASH) [43]	11 items, organized into 4 different physical activities measuring frequency, duration and intensity (physical activity to and from home, household activities, activities at work and physical activities performed during leisure time)	X	X	X	X	X
Tumor hypoxia and immune cell infiltration	Two tumor biopsies: from routine diagnostic investigation and from surgical tumor excision	Immunohistochemistry analysis will be performed for hypoxia and immune cell infiltration biomarkers using the laboratory of the Karolinska Institutet (Sweden) and their according protocols	X		X		
Cost-effectiveness	EuroQol 5-dimension (EQ-5D-5L) [44]	5 items (dimensions) multi-attribute utility questionnaire that measures mobility, self-care, usual activities, pain/discomfort and anxiety/depression in 5 levels	X	X	X	X	X
	iMTA medical consumption questionnaire (iMCQ) [45] and productivity costs questionnaire (iPCQ) [46]	Patient reported productivity losses and medical consumption		X	X	X	X
	Health care costs	Medical activities abstracted from the management systems of the hospitals					X
<b>Other outcomes</b>							
Sociodemographic and clinical data	Sociodemographic data, disease, and treatment characteristics will be abstracted from medical records or reported by the patient	Patient reported: place of birth, sex, marital status, living and work situation, education, lifestyle variables, and the self-administrated comorbidity questionnaire [47]  Medical records: birth month and year, date of diagnosis, date and type of treatment, type of urinary diversion, tumor characteristics, ASA score, WHO score  Patient reported: smoking status	X				
			X	X	X	X	X
Coping mechanism	Sense of coherence questionnaire [48]	13 items, categorized into three scales: comprehensibility, manageability, meaningfulness	X				
Compliance to the intervention	Adherence rates	Patient reported: self-composed (activity) diary	X	X	X		
		Physical therapist: adherence of the physical exercise training intervention on standardized training session forms					
Patient evaluation	Self-composed questionnaire	Patients in the intervention group: satisfaction with the program and willingness to participate in focus group  Patients in the control group: evaluate contamination  Both groups: evaluation of possible post-surgical intervention					X
Non-participation	Self-composed questionnaire	Patient reported outcomes: sociodemographic, health- and bladder cancer-related quality of life, anxiety and depression, fatigue, physical activity, coping mechanism, and reason(s) for not participating  Medical records: birth month and year, date of diagnosis, date and type of treatment, tumor characteristics, ASA score, WHO score	X				

### **Control group– standard-of-care**

Patients randomized to the standard-of-care arm receive care as usual, which does not include a comprehensive multimodal prehabilitation program. In all participating centers, enhanced recovery after surgery protocols are used to optimize medical conditions to enhance recovery [49]. These protocols include advice on smoking cessation when a patient is smoking and a referral to a dietician when malnutrition is detected. Preoperatively, the urologist determines whether the patient is physically fit for surgery. Patients in the control group are not prohibited to be physically active or seek counselling for nutritional advice, psychological support, or smoking cessation.

### **Intervention group– prehabilitation**

Patients randomized to the intervention arm will participate in a multimodal prehabilitation program including supervised physical exercise training, nutritional support, and – when relevant – psychological counseling and professional support for smoking-cessation, to enhance their health status. The intervention starts as soon as possible after baseline measurements and randomization, approximately 3-6 weeks before surgery, and is continued until surgery. Patients who are included before undergoing neoadjuvant treatment (including chemotherapy and immunotherapy) will participate in a physical exercise training program from inclusion until completion of neoadjuvant treatment to prevent the often observed decline in physical fitness throughout neoadjuvant therapy. Subsequently, these patients will participate in the full multimodal prehabilitation program until the date of surgery. Adverse events related to the intervention are monitored.

### ***Physical exercise training program***

The physical exercise training program consists of three training sessions per week under the supervision of a physical therapist. An overview of the training program and training progression is described in Table 2. The program will be delivered at a physical therapy practice near a patient's home to minimize travel time, preferably supervised by a physical therapist affiliated with Onconet, a nationwide network of physical therapists with additional competencies in cancer care. The study coordinator provides the physical therapists instructions via a video call covering the specifics of the training program for the current study.



Table 2. Content of the supervised physical exercise training program in the intervention group

Frequency	Intensity	Time	Type
Three times a week	Aerobic interval training, consisting of 4 intervals of alternating effort performed on a cycle ergometer: - 4 min of low-intensity exercise, defined as 30% of the workload achieved at VO <sub>2</sub> peak - 2-3 min of high-intensity exercise, defined as 90% of the workload achieved at VO <sub>2</sub> peak <sup>a</sup>	24-28 min	Aerobic interval training
Two times a week	During neoadjuvant treatment: <b>Week 1 – 3:</b> consisting of 20 minutes on a cycle ergometer and 10 minutes on a different aerobic machine, corresponding to 30% of the heart rate reserve <b>Week 4 – 6:</b> consisting of 20 minutes on a cycle ergometer and 10 minutes on a different aerobic machine, corresponding to 40% of the heart rate reserve <b>Week 7 – 9:</b> consisting of 20 minutes on a cycle ergometer and 10 minutes on a different aerobic machine, corresponding to 50% of the heart rate reserve <b>Week 10 – 12 (and further):</b> consisting of 20 minutes on a cycle ergometer and 10 minutes on a different aerobic machine, corresponding to 60% of the heart rate reserve	30 min	Aerobic training
Two times a week	Resistance training, consisting of training six large muscle groups (leg press, bench press or chest press, abdominal crunch, pull over, low row, and step up) <sup>b</sup> in 2 sets: - Week 1: maximal 15 repetitions at ~65% of 1RM per set - Week 2: maximal 12 repetitions at ~70% of 1RM per set (weight week 1 +10%) - Week 3: maximal 10 repetitions at ~75% of 1RM per set (weight week 2 +10%) - From week 4 maximal 10 repetitions per set <sup>c</sup>	~20 min	Resistance training
Once a week	Progressive muscle relaxation techniques [50]	~20 min	Relaxation exercises

Abbreviations: 1RM=one-repetition maximum; CPET=cardiopulmonary exercise test; VO<sub>2</sub>peak=oxygen uptake at peak exercise.

<sup>a</sup> Further tailoring is done by the physical therapists: if a patient is not able to complete the high-intensity interval, the intensity will be reduced by 10%. The intensity can be reduced further in steps of 10% until the patient can complete all four high-intensity intervals. If a patient is able to complete all high-intensity intervals, moderate and high intensity will be increased by 10% [51]. During neoadjuvant treatment [52]: if a patient scores below a Borg score of 12 intensity is increased, if a patient scores above a Borg score of 15 intensity is decreased.

<sup>b</sup> Physical therapists can offer alternative resistance exercises targeting the same muscle group to accommodate a patient's abilities and preferences.

<sup>c</sup> If the patient is able to do two repetitions more than planned, the load will be increased by 10%. The load will be decreased by 10% if the patient is not able to achieve the planned number of repetitions.

Training sessions last one hour and consist of individualized aerobic interval training (three times a week), resistance training (two times a week), and relaxation exercises (once a week). Results of the CPET will be used to establish the individual training intensity for aerobic interval training. For the resistance training, six large muscle groups will be targeted, in two sets of a defined maximum number of repetitions. The aim of these training sessions is to improve cardiorespiratory fitness, and muscle strength and mass. Relaxation exercises consist of guided breathing exercises and progressive muscle relaxation [50]. The aim of these exercises is to reduce possible anxiety and stress. In addition to the supervised sessions, patients are encouraged to be moderately active on at least two additional days per week for 30 minutes.

1  
2  
3 The supervised sessions during neoadjuvant treatment consist of twice-weekly moderate-intensity  
4 aerobic and resistance training. Patients receive the physical exercise training program as described  
5 above for the remaining 3-6 weeks before surgery.  
6  
7

### 8 9 ***Nutritional support***

10 Patients receive tailored advice from a registered dietician at the participating hospitals aiming at a total  
11 protein intake of 1.9-2.3 g/per kg of fat-free mass as estimated with bioelectrical impedance analysis, to  
12 promote an anabolic state. Dietary advice will emphasize the benefit of spreading protein consumption  
13 over three meals, with a goal of 25-30 g protein per meal, and includes advice for optimal energy intake.  
14 To achieve this, and to increase adaptive responses of the skeletal muscle, participants will receive high-  
15 quality protein supplements containing 30 g of whey protein, 20 microgram of vitamin D, and 250 mg of  
16 calcium [53] in standardized supplements produced for the purpose of the study (FrieslandCampina, The  
17 Netherlands). These supplements are prescribed after each physical exercise training session and daily  
18 at least one hour before sleep or in the morning (depending on the patient's preference). The dietician  
19 provides intake consultation and one or two follow-up sessions to evaluate nutritional intake. Protein  
20 intake will be restricted according to the severity of renal impairment. Depending on the patient's  
21 protein intake, patients will be advised to either reduce or drop the intake of protein supplements. If  
22 necessary, additional dietary advices will be provided to reduce nutritional protein intake. Nutritional  
23 support starts at 3-6 weeks before surgery for all patients.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33

### 34 35 ***Psychological counseling***

36 Patients are screened for anxiety and depression using the hospital anxiety and depression scale (HADS)  
37 questionnaire at baseline [41]. If a patient's score falls between 11 and 18, the option of psychological  
38 counselling is discussed, and referral is arranged for patients indicating a need for such counselling.  
39 Patients who score  $\geq 19$  are directly referred to psychological counselling. Referred patients receive an  
40 initial counselling session of 1.5 hours, and additional sessions at the discretion of the psychological  
41 counsellor and the patient.  
42  
43  
44  
45  
46

### 47 48 ***Smoking cessation***

49 Intensive counselling and nicotine replacement therapy is offered to all smoking patients in the 3-6  
50 weeks before surgery. Counselling includes at least one in-person session and one or more telephone or  
51 in-person follow-up sessions by trained counsellors. If the patient indicates to be smoking and is willing  
52 to quit, the treating physician will refer the patient.  
53  
54  
55  
56  
57  
58  
59  
60

## Study outcomes

Data are collected before randomization (T0a), before surgery (T1), and 4 (T2), and 12 (T3) weeks after surgery. If applicable, additional data will be collected after neoadjuvant treatment (T0b). At T0a, clinical data (e.g., treatment, clinical stage) will be abstracted from the medical records and sociodemographic characteristics (e.g., age, sex, education) will be obtained via a questionnaire. In addition, coping mechanisms [54] will be assessed via a questionnaire as this can help understand participation, attendance, and dropouts. Data is collected in CastorEDC and access is restricted to the investigator team. Due to the low risk of the intervention a data safety monitoring board is not instated.

### Primary outcome

The primary outcome is the proportion of patients who develop one or more grade  $\geq 2$  perioperative complications within 90 days after surgery. Complications are graded according to the Clavien-Dindo classification system [55] as described in Table 3.

Table 3. The Clavien-Dindo classification of surgical complications

Grade	Definition
Grade I	Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic and radiological interventions Allowed therapeutic regimens are: drugs as antiemetics, antipyretics, analgetics, diuretics and electrolytes and physical therapy This grade also includes wound infections opened at the bedside
Grade II	Requiring pharmacological treatment with drugs other than such allowed for grade I complications Blood transfusions and total parenteral nutrition are also included
Grade III	Requiring surgical, endoscopic, or radiological intervention
-IIIa	Intervention not under general anesthesia
-IIIb	Intervention under general anesthesia
Grade IV	Life-threatening complication (including CNS complications) <sup>a</sup> requiring IC/ICU-management
-IVa	Single organ dysfunction (including dialysis)
-IVb	Multiorgan dysfunction
Grade V	Death of a patient

Adapted from [55].

Abbreviations: CNS=central nervous system; IC=intermediate care; ICU=intensive care unit.

<sup>a</sup> brain hemorrhage, ischemic stroke, subarachnoidal bleeding, but excluding transient ischemic attacks (TIA)

### *Secondary outcomes*

Secondary outcomes are the proportion of patients who develop one or more high-grade (grade  $\geq 3$ ) complications, total number of complications, length of hospital stay, number of readmissions, disease status (progression/recurrence), and additional treatment within 90 days. Secondary outcomes also include the intermediate outcomes of the intervention: cardiorespiratory fitness (measured using the standardized CPET [34]), physical functioning, upper and lower extremity (functional) muscle strength, nutritional intake, nutritional status, body composition, health-related quality of life, bladder cancer-related quality of life, anxiety and depression, fatigue, physical activity, and adherence to the intervention. Direct and indirect costs are collected for the cost-effectiveness analysis. Tumor hypoxia, immune cell infiltration, and pathological response are assessed as explorative outcomes. Participants in the control group will be asked whether they participated in any (structured) lifestyle program during the preoperative period, to monitor contamination. In both groups, participants will be asked whether they received any postoperative intervention. The timing and type of outcome measures are presented in Table 1.

### *Costs*

For direct costs in both groups, medical records will be used to gather data on treatment, complications, length of hospital stay and number of readmissions, follow up, and diagnostics. For the intervention group, the costs for the prehabilitation program, including physical exercise training, nutritional support, psychological counseling, and smoking cessation, will be determined by means of the activity-based costing (ABC) [56] method. Costs for neo-adjuvant treatment are expected to be equal for both arms and will therefore not be included in the calculation. For indirect costs, the iMTA medical consumption questionnaire (iMCQ) [45] will be used, to gather data on medical consumption outside the hospital. The iMCQ includes questions related to frequently occurring contacts with health care providers. For patients who currently have remunerative employment, productivity losses will be obtained through the iMTA productivity costs questionnaire (iPCQ) [46]. To calculate quality-adjusted life years, utilities will be derived from the EuroQoL 5-dimension (EQ-5D-5L) questionnaire [44].

### *Compliance*

To monitor therapeutic validity, compliance with the physical exercise training program is assessed by attendance rates and compliance to all parts of the training program as scored by the physical therapist on standardized training session forms, as well as by patient self-report via an activity diary. Compliance

1  
2  
3 to nutritional supplement intake is assessed via a diary. Whether smoking cessation has been successful  
4 is assessed through questionnaires.  
5

### 6 7 *Satisfaction*

8  
9 Patients in the intervention group are asked to complete a short questionnaire at the end of the study  
10 about the perceived effectiveness of and satisfaction with the program, whether they would suggest any  
11 changes, and whether they would recommend it to other patients with bladder cancer. In addition,  
12 patients will be asked if they are willing to be contacted for participation in a focus group where the  
13 intervention program and changes that may positively affect implementation will be further discussed.  
14  
15

### 16 17 18 **Sample size calculation**

19  
20 Previous studies in diverse types of cancer reported a reduction of postoperative complications in the  
21 intervention group compared to the control group, with odds ratios ranging from 0.11 to 0.88 [57-63].  
22 This study aims to reduce the number of patients with any grade  $\geq 2$  perioperative complication within  
23 90 days from 60% [64, 65] to 35% (relative risk 0.58, odds ratio 0.36) [66, 67]. Assuming a two-sided  
24 Fisher exact test with a power of 80% and an alpha of 0.05, in total 140 patients will be needed. To  
25 account for 10% dropout, including dropout due to cancelling of the planned surgery, 154 patients will  
26 be included. Approximately 380 patients with bladder cancer undergo RC in the eight participating  
27 hospitals annually. This implies that it is feasible to complete inclusion within two and a half years, if  
28 recruitment rate is at least 17%.  
29  
30  
31  
32  
33  
34  
35

### 36 37 **Statistical analysis**

#### 38 *Primary outcome*

39  
40 All analyses will be performed on an intention-to-treat basis. Descriptive statistics will be calculated to  
41 describe and evaluate the comparability of the two groups at baseline on sociodemographic and clinical  
42 variables, and to assess the adequacy of the randomization. Patients who do not receive the planned  
43 surgery or have an open-closed procedure, independent of group allocation, will be excluded from the  
44 primary analysis. The proportion of patients who develop any grade  $\geq 2$  complications will be compared  
45 in the two study arms by using Fisher's exact test and a Poisson regression model with a log link,  
46 adjusted for the stratification factors and relevant baseline imbalances. The relative risk will be reported  
47 with a 95% confidence interval based on robust standard errors [68].  
48  
49  
50  
51  
52  
53

#### 54 *Secondary study outcomes*

55  
56 Between-group differences over time will be evaluated in measures of physical functioning and patient-  
57  
58  
59  
60

1  
2  
3 reported outcomes using linear mixed effects regression analysis. For high-grade complications, length  
4 of hospital-stay, and number of readmissions, Poisson regression models with an appropriate link  
5 function will be used. For continuous outcomes, differences in mean change scores between the two  
6 study arms will be accompanied by effect sizes. Standardized effect sizes will be calculated by  
7 subtracting the mean change scores of the control group from those of the intervention group, and  
8 subsequently dividing this by the pooled standard deviation. Effect sizes of 0.2 are considered small, 0.5  
9 moderate, and 0.8 large [69]. A  $p$ -value  $<0.05$  will be considered statistically significant.

### 15 *Intervention fidelity*

16 Descriptive statistics will be used to summarize compliance rates of the supervised exercise sessions as  
17 well as home based physical activity, supplement consumption, and smoking cessation. Compliance  
18 rates are based on number of completed training sessions, supplementation consumption, and number  
19 of patients who stop smoking in the study intervention. Whether the level of compliance is associated  
20 with changes over time in primary and secondary study outcomes will be evaluated using generalized  
21 linear mixed effects models.

### 27 *Non-participants*

28 Baseline data of participants will be compared to those of non-participants using chi-squared statistics  
29 for categorical variables and analysis of variance for continuous variables.

### 33 *Exploratory analysis*

34 Exploratory analyses will be performed to explore the moderating effect of intervention duration, and  
35 differences in effectiveness of the physical exercise training program between those who received  
36 neoadjuvant chemotherapy and those who did not. This will be done by adding interaction terms to the  
37 model and by performing stratified analyses if the interaction term is statistically significant at  $p<0.10$ .  
38 Exploratory analyses will also be executed to study the relationship of post-intervention/preoperative  
39 physical fitness parameters (i.e.,  $VO_2$ peak) and nutritional status, with perioperative outcomes (grade  $\geq 2$   
40 complications yes/no and number of days in the hospital. For this analysis, univariable and multivariable  
41 Poisson regression analyses will be used.

### 47 **Economic evaluation**

48 A trial- and model-based economic evaluation will be performed, based on the intention-to-treat  
49 analysis. The model-based evaluation will use literature for the potential long-term consequences and  
50 parametric survival methods to extrapolate the trial data beyond the included follow-up. The analysis  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 will be approached from a societal perspective of The Netherlands and a lifelong time horizon. A Markov  
4 decision model will be built, with relevant health states derived from the EQ-5D-5L questionnaire.  
5 Outcomes are 1) the incremental costs per reduced proportion of patients who develop one or more  
6 grade  $\geq 2$  perioperative complications within 90 days (trial-based), and 2) incremental costs, incremental  
7 quality-adjusted life years, and the incremental cost-effectiveness ratio (ICER) (model-based). An  
8 estimation of the degree of uncertainty around each input parameter will be included with the use of  
9 probabilistic sensitivity analyses. Parameter values will be drawn randomly from the assigned  
10 distributions, using Monte Carlo simulations [70]. To capture necessary support regarding adoption and  
11 further research, value of information (VOI) analyses will be performed [71]. Where appropriate, Dutch  
12 guidelines for costing studies will be used in applying tariffs to units of resource use [72]. Finally, a  
13 budget impact analysis will be performed according to the ISPOR guidelines [73].  
14  
15  
16  
17  
18  
19  
20  
21

### 22 **Patient and public involvement**

23 Patients or the public were not involved in the development of the study design. A patient  
24 representative is currently involved in the study and input will be obtained whenever relevant during  
25 the trial. Annual consortium meetings with the urologists are organized.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## DISCUSSION

A considerable proportion of patients with bladder cancer scheduled for RC has a poor cardiorespiratory fitness [9, 10], is malnourished [11, 74], and/or is an active smoker at diagnosis [75]. This implies that there is a substantial potential for improving cardiorespiratory fitness and nutritional status in this patient population. Here, the rationale and design of a multimodal prehabilitation program for patients with bladder cancer who are scheduled for RC is presented. It is hypothesized that the program will be effective in reducing the number and severity of perioperative complications.

This study has several strengths, including its multicenter, randomized design, the use of an intention-to-treat basis for the data analysis, and a minimization technique to ensure blinded treatment allocation and comparable groups. Most importantly, the study intervention consists of a tailored program for physical exercise training and nutritional support following current best-practice for prehabilitation. Moreover, a cost-effectiveness analysis will be performed to anticipate smooth implementation and reimbursement, and tumor hypoxia and immune cell infiltration analysis will be performed exploratively. Intervention fidelity will be monitored in detail, as recommended previously [76], as will adverse events related to the intervention. Another notable strength is the additional analysis in non-participants. Selective non-participation is a serious risk for the generalizability of physical exercise training studies. Previous physical exercise training studies in other cancer populations have shown relevant differences between those who participate and those who do not [77, 78]. It has previously been described that patients who were eligible for prehabilitation programs for colon cancer surgery expressed several reservations [79]. It is vital to understand the characteristics of non-participants and reasons for non-participation in bladder cancer prehabilitation. This will not only help judge the generalizability of the results but will also support implementation in a way that will maximize the potential value of the prehabilitation program and achieve equitable health outcomes. Finally, the exploratory subgroup analysis in patients who receive neoadjuvant treatment might be relevant to inform future studies on risk stratification.

To limit barriers to participation and adherence, the exercise program will be delivered as near to the patients' homes as possible, to minimize travel time. This is a very important factor for patients with cancer according to previous studies [67, 80-82]. The availability of and close collaboration with the nationwide Onconet network of physical therapists, who are specifically educated to supervise patients with cancer, is an important advantage. An additional benefit of this approach is that it will facilitate implementation if the intervention proves to be effective.



1  
2  
3 This study also has some limitations. Patients with bladder cancer will be followed for a period of 90  
4 days after surgery, meaning that longer-term evaluation of outcomes will not be possible. Because up to  
5 60% of patients report complications within 90 days after surgery [83], it is expected that the time frame  
6 will be adequate for our primary outcome. A possible limitation is the risk of contamination in the  
7 control group. An evaluation questionnaire will be used in the control group to determine whether  
8 patients were physically active or received a (structured) lifestyle intervention pre- and postoperatively.  
9 Although objective measurements of habitual physical activity may provide a more detailed insight into  
10 physical activity levels not prone to recall bias, the collection of physical activity levels will be restricted  
11 to using questionnaires for feasibility reasons. This program is designed to maximally improve a patient's  
12 health status by including physical exercise training, nutritional support, psychological counseling and  
13 smoking cessation. It is not likely that patients who are randomized to the control group would initiate a  
14 program consisting of all these components on their own. The multimodal approach prohibits  
15 disentangling of the individual effects of each lifestyle component in the prehabilitation program.  
16 Considering the number of intervention components and the prevalence of bladder cancer, a larger  
17 study using a full factorial design is unlikely to be feasible in this population. Moreover, the current best-  
18 practice for other types of cancer supports the use of multimodal interventions over unimodal  
19 approaches [84, 85]. Higher levels of physical exercise training have been demonstrated to be beneficial  
20 for both cancer prevention and, in some solid tumors, progression of disease and cancer-related  
21 mortality [86, 87]. However, the underlying biological mechanism has yet to be demonstrated. It is  
22 expected that the prehabilitation program has positive effects on the tumor microenvironment. The  
23 hypoxic tumor microenvironment is a common characteristics of a solid tumor when oxygen levels  
24 become low, as a result of the rapid proliferation of tumor cells [88] and is linked to poor prognosis in  
25 bladder cancer [89]. Physical exercise training has regulatory effects on the angiogenesis of skeletal  
26 muscles, which has raised interest in whether these effects might translate to solid tumors [90].  
27 Preclinical research has shown that training may acutely reduce tumor hypoxia through vascular  
28 normalization and thereby improve the perfusion of tumor tissue [91-94]. In addition, exercise training  
29 has been suggested to alter immune cell infiltration in solid tumors and thereby contribute to enhanced  
30 immune surveillance and improved vascular function [25]. However, current evidence is inconsistent  
31 and inconclusive [95]. Clinical trials are very limited and this preoperative setting provides an excellent  
32 opportunity to investigate the potential role of prehabilitation on tumor hypoxia and immune cell  
33 infiltration.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 To summarize, this study will provide empirical evidence on the benefits of multimodal prehabilitation  
4 for patients with bladder cancer planned for RC who are at high risk of perioperative complications and  
5 a long recovery period. When proven (cost-)effective, the study results will support implementation of a  
6 multimodal prehabilitation program for patients with bladder cancer in daily clinical practice.  
7  
8  
9

10 **Figure caption**

11 **Figure 1.** Study flow chart  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

### Author affiliations

<sup>1</sup> Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

<sup>2</sup> Center for Quality of Life, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

<sup>3</sup> Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands

<sup>4</sup> Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden

<sup>5</sup> Department of Oncological Urology, University Medical Center Utrecht, Utrecht, The Netherlands

<sup>6</sup> Department of Urology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands

<sup>7</sup> Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands

<sup>8</sup> Department of Urology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands

<sup>9</sup> Department of Urology, Catharina Hospital, Eindhoven, The Netherlands

<sup>10</sup> Department of Urology, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands

<sup>11</sup> Department of Urology, Rijnstate Hospital, Arnhem, The Netherlands

<sup>12</sup> Department of Urology, Maastricht University Medical Center+, Maastricht, The Netherlands

<sup>13</sup> Department of Nutrition and Movement Sciences, Nutrition and Translational Research in Metabolism (NUTRIM), Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands

<sup>14</sup> Department of Epidemiology, Care and Public Health Research Institute (CAPHRI), Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands

<sup>15</sup> Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands

<sup>16</sup> Department of Health Technology and Services Research, University of Twente, Enschede, The Netherlands

<sup>17</sup> Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands

<sup>18</sup> Department of Medicine for older people, Amsterdam UMC, Amsterdam Public Health & Amsterdam Movement Sciences, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands

<sup>19</sup> Centre of Expertise Urban Vitality, Faculty of Health, Amsterdam University of Applied Sciences, Amsterdam, The Netherlands

### Authors' contributions

AV, AL, AH, EK, VPR, WH, AM, WG, and MMS conceived the study. AV, WH, AM, WG, MMS, MGS, and EA contributed to the design of the study protocol. RM, AL, AH, VCR, EK, SB, CW, TM, and BB reviewed the study protocol with a clinical perspective. VPR wrote the statistical approach of the economic evaluation. HR composed the protocol of tumor hypoxia and immune cell infiltration analysis. AV, WH, AM, WG, MMS, MGS, and EA wrote the manuscript. All authors read, commented on, and approved the manuscript.

### Funding

This work was supported by the Dutch Cancer Society (KWF, Delflandlaan 17, 1062 EA, Amsterdam, The Netherlands), grant number NKI 2020-1/12877. The funder has no role in the design, data collection, and analysis of the study.

### Acknowledgements

Research at the Netherlands Cancer Institute is supported by institutional grants of the Dutch Cancer Society and of the Dutch Ministry of Health, Welfare and Sport. The protein supplements in the clinical study will be kindly provided by FrieslandCampina.

### Competing interests

CW received a research grant from ZonMw and gives courses on robot assisted radical cystectomy during conferences entitled with EAU. TM received consulting fees as member of the advisory board prostate cancer of Janssen-Cilag B.V.. BB participates on a Data Safety Monitoring Board of an international prehabilitation study, is board member of Netherlands Society of Human Movement sciences, member of Exercise is Medicine of Vereniging voor Sportgeneeskunde, and member of the Scientific Committee of Fit4Surgery. RM received research grants from Janssen, Roche and Astellas, an educational grant from Merck, received consulting fees from Merck, MSD, Janssen, Bristol-Myers Squibb Company, received support for attending the 2022 Global Congress on Bladder Cancer, and is EAU Panel member of the Muscle Invasive Bladder Cancer Guideline. MMS is member of the Scientific Committee of Fit4Surgery and board member of Onconet.

### Patient consent for publication

Not applicable.

1. Sung, H., et al., *Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries*. CA: a cancer journal for clinicians, 2021. **71**(3): p. 209-249.
2. Stein, J.P. and D.G. Skinner, *Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure*. World journal of urology, 2006. **24**(3): p. 296-304.
3. Witjes, J.A., et al., *Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer*. European urology, 2017. **71**(3): p. 462-475.
4. Babjuk, M., et al., *European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)*. European urology, 2021.
5. Maibom, S.L., et al., *Short-term morbidity and mortality following radical cystectomy: a systematic review*. BMJ open, 2021. **11**(4): p. e043266.
6. Shabsigh, A., et al., *Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology*. European urology, 2009. **55**(1): p. 164-176.
7. Novara, G., et al., *Complications and mortality after radical cystectomy for bladder transitional cell cancer*. The Journal of urology, 2009. **182**(3): p. 914-921.
8. Bochner, B.H., D.D. Sjoberg, and V.P. Laudone, *A randomized trial of robot-assisted laparoscopic radical cystectomy*. New England journal of medicine, 2014. **371**(4): p. 389-390.
9. Prentis, J.M., et al., *Impaired cardiopulmonary reserve in an elderly population is related to postoperative morbidity and length of hospital stay after radical cystectomy*. BJU international, 2013. **112**(2): p. E13-E19.
10. Tolchard, S., et al., *Cardiopulmonary reserve as determined by cardiopulmonary exercise testing correlates with length of stay and predicts complications after radical cystectomy*. BJU international, 2015. **115**(4): p. 554-561.
11. Arora, K., et al., *Early complications and mortality following radical cystectomy: associations with malnutrition and obesity*. Bladder Cancer, 2018. **4**(4): p. 377-388.
12. Mavros, M.N., et al., *Do psychological variables affect early surgical recovery?* PloS one, 2011. **6**(5): p. e20306.
13. Sathianathen, N.J., et al., *Increased surgical complications in smokers undergoing radical cystectomy*. Bladder Cancer, 2018. **4**(4): p. 403-409.
14. Jack, S., et al., *The effect of neoadjuvant chemotherapy on physical fitness and survival in patients undergoing oesophagogastric cancer surgery*. European Journal of Surgical Oncology (EJSO), 2014. **40**(10): p. 1313-1320.
15. West, M., et al., *Cardiopulmonary exercise testing for the prediction of morbidity risk after rectal cancer surgery*. Journal of British Surgery, 2014. **101**(9): p. 1166-1172.
16. Sinclair, R., et al., *The impact of neoadjuvant chemotherapy on cardiopulmonary physical fitness in gastro-oesophageal adenocarcinoma*. The Annals of The Royal College of Surgeons of England, 2016. **98**(6): p. 396-400.
17. Thomson, I.G., et al., *Neoadjuvant therapy reduces cardiopulmonary function in patients undergoing oesophagectomy*. International Journal of Surgery, 2018. **53**: p. 86-92.
18. Banerjee, S., et al., *Vigorous intensity aerobic interval exercise in bladder cancer patients prior to radical cystectomy: a feasibility randomised controlled trial*. Supportive Care in Cancer, 2018. **26**(5): p. 1515-1523.
19. Kaye, D.R., et al., *The feasibility and impact of a Presurgical exercise intervention program (Prehabilitation) for patients undergoing cystectomy for bladder cancer*. Urology, 2020. **145**: p. 106-112.
20. Jensen, B.T., et al., *Efficacy of a multiprofessional rehabilitation programme in radical cystectomy pathways: a prospective randomized controlled trial*. Scandinavian journal of urology, 2015. **49**(2): p. 133-141.

- 1
- 2
- 3
- 4 21. Minnella, E.M., et al., *Multimodal prehabilitation to enhance functional capacity following radical cystectomy: a randomized controlled trial*. *European Urology Focus*, 2021. **7**(1): p. 132-138.
- 5
- 6
- 7 22. Jensen, B.T., et al., *Exercise-based pre-habilitation is feasible and effective in radical cystectomy pathways—secondary results from a randomized controlled trial*. *Supportive Care in Cancer*, 2016. **24**(8): p. 3325-3331.
- 8
- 9
- 10 23. Thomas, G., et al., *Prehabilitation before major intra-abdominal cancer surgery: a systematic review of randomised controlled trials*. *European journal of anaesthesiology*, 2019. **36**(12): p. 933.
- 11
- 12
- 13 24. Wiggins, J.M., et al., *Exercise and the tumor microenvironment: potential therapeutic implications*. *Exercise and sport sciences reviews*, 2018. **46**(1): p. 56-64.
- 14
- 15 25. Zhang, X., et al., *Can Exercise-Induced Modulation of the Tumor Physiologic Microenvironment Improve Antitumor Immunity? Exercise, Immunity, and Physiologic Microenvironment*. *Cancer research*, 2019. **79**(10): p. 2447-2456.
- 16
- 17
- 18 26. Shannon, A.M., et al., *Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies*. *Cancer treatment reviews*, 2003. **29**(4): p. 297-307.
- 19
- 20 27. Peixoto, A., et al., *Hypoxia enhances the malignant nature of bladder cancer cells and concomitantly antagonizes protein O-glycosylation extension*. *Oncotarget*, 2016. **7**(39): p. 63138.
- 21
- 22 28. Boström, P., et al., *Hypoxia marker GLUT-1 (glucose transporter 1) is an independent prognostic factor for survival in bladder cancer patients treated with radical cystectomy*. *Bladder Cancer*, 2016. **2**(1): p. 101-109.
- 23
- 24
- 25
- 26 29. Pocock, S.J. and R. Simon, *Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial*. *Biometrics*, 1975: p. 103-115.
- 27
- 28 30. Jin, M., A. Polis, and J. Hartzel. *R package 'Minirand'. 0.1.3. ed. CRAN*. 2020; Available from: <https://cran.r-project.org/web/packages/Minirand/Minirand.pdf>.
- 29
- 30 31. Jin, M., A. Polis, and J. Hartzel, *Algorithms for minimization randomization and the implementation with an R package*. *Communications in Statistics-Simulation and Computation*, 2021. **50**(10): p. 3077-3087.
- 31
- 32
- 33 32. Campbell, K.L., et al., *Exercise guidelines for cancer survivors: consensus statement from international multidisciplinary roundtable*. *Medicine and science in sports and exercise*, 2019. **51**(11): p. 2375.
- 34
- 35 33. Rock, C.L., et al., *American Cancer Society nutrition and physical activity guideline for cancer survivors*. *CA: A Cancer Journal for Clinicians*, 2022. **72**(3): p. 230-262.
- 36
- 37 34. Berkel, A.E., et al., *The effects of prehabilitation versus usual care to reduce postoperative complications in high-risk patients with colorectal cancer or dysplasia scheduled for elective colorectal resection: study protocol of a randomized controlled trial*. *BMC gastroenterology*, 2018. **18**(1): p. 1-14.
- 38
- 39 35. Guralnik, J.M., et al., *A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission*. *Journal of gerontology*, 1994. **49**(2): p. M85-M94.
- 40
- 41 36. Langius, J., et al., *Meetprotocol handknijpkracht mbv Hand Dynamometer*. *Nutritional Assessment Platform*, 2016.
- 42
- 43 37. McAllister, L.S. and K.M. Palombaro, *Modified 30-second sit-to-stand test: reliability and validity in older adults unable to complete traditional sit-to-stand testing*. *Journal of Geriatric Physical Therapy*, 2020. **43**(3): p. 153-158.
- 44
- 45 38. Bauer, J., S. Capra, and M. Ferguson, *Use of the scored Patient-Generated Subjective Global Assessment (PG-SGA) as a nutrition assessment tool in patients with cancer*. *European journal of clinical nutrition*, 2002. **56**(8): p. 779-785.
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60


- 1  
2  
3  
4 39. Aaronson, N.K., et al., *The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology*. JNCI: Journal of the National Cancer Institute, 1993. **85**(5): p. 365-376.
- 5  
6  
7 40. Danna, B.J., et al., *Assessing symptom burden in bladder cancer: an overview of bladder cancer specific health-related quality of life instruments*. Bladder cancer, 2016. **2**(3): p. 329-340.
- 8  
9 41. Zigmond, A.S. and R.P. Snaith, *The hospital anxiety and depression scale*. Acta psychiatrica scandinavica, 1983. **67**(6): p. 361-370.
- 10  
11 42. Smets, E., et al., *The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue*. Journal of psychosomatic research, 1995. **39**(3): p. 315-325.
- 12  
13 43. Wendel-Vos, G.W., et al., *Reproducibility and relative validity of the short questionnaire to assess health-enhancing physical activity*. Journal of clinical epidemiology, 2003. **56**(12): p. 1163-1169.
- 14  
15 44. Uyl-de Groot, C.A., F.F. Rutten, and G.J. Bonsel, *Measurement and valuation of quality of life in economic appraisal of cancer treatment*. European Journal of Cancer, 1994. **30**(1): p. 111-117.
- 16  
17 45. Bouwmans, C., et al., *Medical cost questionnaire (iMCQ)*. Rotterdam: iMTA, Erasmus Universiteit Rotterdam, 2013.
- 18  
19 46. Bouwmans, C., et al., *Productivity Cost Questionnaire*. Erasmus University Rotterdam: Institute for Medical Technology Assesment, 2013.
- 20  
21 47. Sangha, O., et al., *The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research*. Arthritis Care & Research: Official Journal of the American College of Rheumatology, 2003. **49**(2): p. 156-163.
- 22  
23 48. Antonovsky, A., *The structure and properties of the sense of coherence scale*. Social science & medicine, 1993. **36**(6): p. 725-733.
- 24  
25 49. Cerantola, Y., et al., *Guidelines for perioperative care after radical cystectomy for bladder cancer: Enhanced Recovery After Surgery (ERAS®) society recommendations*. Clinical nutrition, 2013. **32**(6): p. 879-887.
- 26  
27 50. Jacobson, E., *You must relax*. 1934.
- 28  
29 51. van Rooijen, S., et al., *Multimodal prehabilitation in colorectal cancer patients to improve functional capacity and reduce postoperative complications: the first international randomized controlled trial for multimodal prehabilitation*. BMC cancer, 2019. **19**(1): p. 1-11.
- 30  
31 52. Swain, D.P., C.A. Brawner, and A.C.o.S. Medicine, *ACSM's resource manual for guidelines for exercise testing and prescription*. 2014: Wolters Kluwer Health/Lippincott Williams & Wilkins.
- 32  
33 53. Cermak, N.M., et al., *Protein supplementation augments the adaptive response of skeletal muscle to resistance-type exercise training: a meta-analysis*. The American journal of clinical nutrition, 2012. **96**(6): p. 1454-1464.
- 34  
35 54. Antonovsky, H. and S. Sagy, *The development of a sense of coherence and its impact on responses to stress situations*. Journal of Social Psychology, 1986. **126**(2): p. 213-226.
- 36  
37 55. Dindo, D., N. Demartines, and P.-A. Clavien, *Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey*. Annals of surgery, 2004. **240**(2): p. 205.
- 38  
39 56. Cooper, R. and R.S. Kaplan, *Profit priorities from activity-based costing*. Harvard business review, 1991. **69**(3): p. 130-135.
- 40  
41 57. Dronkers, J., et al., *Prevention of pulmonary complications after upper abdominal surgery by preoperative intensive inspiratory muscle training: a randomized controlled pilot study*. Clinical rehabilitation, 2008. **22**(2): p. 134-142.
- 42  
43 58. Dronkers, J., et al., *Preoperative therapeutic programme for elderly patients scheduled for elective abdominal oncological surgery: a randomized controlled pilot study*. Clinical rehabilitation, 2010. **24**(7): p. 614-622.
- 44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
59. Kulkarni, S., et al., *Pre-operative inspiratory muscle training preserves postoperative inspiratory muscle strength following major abdominal surgery—a randomised pilot study*. The Annals of The Royal College of Surgeons of England, 2010. **92**(8): p. 700-705.
  60. Barbalho-Moulim, M.C., et al., *Effects of preoperative inspiratory muscle training in obese women undergoing open bariatric surgery: respiratory muscle strength, lung volumes, and diaphragmatic excursion*. Clinics, 2011. **66**(10): p. 1721-1727.
  61. Soares, S.M.d.T.P., et al., *Pulmonary function and physical performance outcomes with preoperative physical therapy in upper abdominal surgery: a randomized controlled trial*. Clinical rehabilitation, 2013. **27**(7): p. 616-627.
  62. van Adrichem, E.J., et al., *Comparison of two preoperative inspiratory muscle training programs to prevent pulmonary complications in patients undergoing esophagectomy: a randomized controlled pilot study*. Annals of surgical oncology, 2014. **21**(7): p. 2353-2360.
  63. Halliday, L.J., et al., *The impact of prehabilitation on post-operative outcomes in oesophageal cancer surgery: a propensity score matched comparison*. Journal of Gastrointestinal Surgery, 2021. **25**(11): p. 2733-2741.
  64. Low, D.E., et al., *Benchmarking complications associated with esophagectomy*. Annals of surgery, 2019. **269**(2): p. 291-298.
  65. Wijburg, C.J., et al., *Robot-assisted radical cystectomy versus open radical cystectomy in bladder cancer patients: a multicentre comparative effectiveness study*. European Urology, 2021. **79**(5): p. 609-618.
  66. Barberan-Garcia, A., et al., *Personalised prehabilitation in high-risk patients undergoing elective major abdominal surgery: a randomized blinded controlled trial*. 2018, LWW.
  67. Berkel, A.E., et al., *Effects of community-based exercise prehabilitation for patients scheduled for colorectal surgery with high risk for postoperative complications: results of a randomized clinical trial*. Annals of surgery, 2022. **275**(2): p. e299.
  68. Zou, G., *A modified poisson regression approach to prospective studies with binary data*. American journal of epidemiology, 2004. **159**(7): p. 702-706.
  69. Cohen, J., *Statistical power analysis for the behavioral sciences*. 2013: Routledge.
  70. Briggs, A., M. Sculpher, and K. Claxton, *Decision modelling for health economic evaluation*. 2006: Oup Oxford.
  71. Vallejo-Torres, L., et al., *Integrating health economics modeling in the product development cycle of medical devices: a Bayesian approach*. International journal of technology assessment in health care, 2008. **24**(4): p. 459-464.
  72. Hakkaart-van Roijen, L., S. Tan, and C. Bouwmans, *Manual for Cost Research: methods and standard cost prices for economic evaluations in health care*. Diemen: Health Care Insurance Board, 2010.
  73. Mauskopf, J.A., et al., *Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices—budget impact analysis*. Value in health, 2007. **10**(5): p. 336-347.
  74. Gregg, J.R., et al., *Effect of preoperative nutritional deficiency on mortality after radical cystectomy for bladder cancer*. The Journal of urology, 2011. **185**(1): p. 90-96.
  75. Barbosa, A.L., et al., *Smoking intensity and bladder cancer aggressiveness at diagnosis*. PLoS One, 2018. **13**(3): p. e0194039.
  76. Bellg, A.J., et al., *Enhancing treatment fidelity in health behavior change studies: best practices and recommendations from the NIH Behavior Change Consortium*. Health psychology, 2004. **23**(5): p. 443.
  77. van Waart, H., et al., *Why do patients choose (not) to participate in an exercise trial during adjuvant chemotherapy for breast cancer?* Psycho-Oncology, 2016. **25**(8): p. 964-970.

- 1  
2  
3 78. Vd Wiel, H.J., et al., *Characteristics of participants and nonparticipants in a blended internet-based physical activity trial for breast and prostate cancer survivors: Cross-sectional study*. JMIR cancer, 2021. **7**(4): p. e25464.
- 4  
5  
6 79. Agasi-Idenburg, C.S., et al., *"I am busy surviving"-Views about physical exercise in older adults scheduled for colorectal cancer surgery*. Journal of geriatric oncology, 2020. **11**(3): p. 444-450.
- 7  
8 80. Ormel, H., et al., *Predictors of adherence to exercise interventions during and after cancer treatment: a systematic review*. Psycho-oncology, 2018. **27**(3): p. 713-724.
- 9  
10 81. Banerjee, S., et al., *Patient perspectives of vigorous intensity aerobic interval exercise prehabilitation prior to radical cystectomy: a qualitative focus group study*. Disability and rehabilitation, 2021. **43**(8): p. 1084-1091.
- 11  
12  
13 82. van Wijk, L., et al., *Improved preoperative aerobic fitness following a home-based bimodal prehabilitation programme in high-risk patients scheduled for liver or pancreatic resection*. British Journal of Surgery, 2022. **109**(11): p. 1036-1039.
- 14  
15  
16 83. Krajewski, W., et al., *How to lower postoperative complications after radical cystectomy—a review*. Central European journal of urology, 2016. **69**(4): p. 370.
- 17  
18 84. Mewes, J.C., et al., *Effectiveness of multidimensional cancer survivor rehabilitation and cost-effectiveness of cancer rehabilitation in general: a systematic review*. The oncologist, 2012. **17**(12): p. 1581-1593.
- 19  
20  
21 85. Lukez, A. and J. Baima. *The role and scope of prehabilitation in cancer care*. in *Seminars in oncology nursing*. 2020. Elsevier.
- 22  
23  
24 86. Moore, S.C., et al., *Association of leisure-time physical activity with risk of 26 types of cancer in 1.44 million adults*. JAMA internal medicine, 2016. **176**(6): p. 816-825.
- 25  
26  
27 87. Friedenreich, C.M., et al., *Physical Activity and Cancer Outcomes: A Precision Medicine Approach*. *Physical Activity and Cancer: A Precision Medicine Approach*. Clinical Cancer Research, 2016. **22**(19): p. 4766-4775.
- 28  
29  
30 88. Petrova, V., et al., *The hypoxic tumour microenvironment*. Oncogenesis, 2018. **7**(1): p. 1-13.
- 31  
32 89. Theodoropoulos, V.E., et al., *Hypoxia-inducible factor 1 $\alpha$  expression correlates with angiogenesis and unfavorable prognosis in bladder cancer*. European urology, 2004. **46**(2): p. 200-208.
- 33  
34 90. Koelwyn, G.J., et al., *Exercise-dependent regulation of the tumour microenvironment*. Nature Reviews Cancer, 2017. **17**(10): p. 620-632.
- 35  
36 91. Jones, L.W., et al., *Effect of aerobic exercise on tumor physiology in an animal model of human breast cancer*. Journal of applied physiology, 2010. **108**(2): p. 343-348.
- 37  
38 92. McCullough, D.J., et al., *Effects of exercise training on tumor hypoxia and vascular function in the rodent preclinical orthotopic prostate cancer model*. Journal of applied physiology, 2013. **115**(12): p. 1846-1854.
- 39  
40  
41 93. Betof, A.S., et al., *Modulation of murine breast tumor vascularity, hypoxia, and chemotherapeutic response by exercise*. JNCI: Journal of the National Cancer Institute, 2015. **107**(5).
- 42  
43  
44 94. Schumacher, O., et al., *Exercise modulation of tumour perfusion and hypoxia to improve radiotherapy response in prostate cancer*. Prostate Cancer and Prostatic Diseases, 2021. **24**(1): p. 1-14.
- 45  
46  
47 95. Seet-Lee, C., et al., *The effect of aerobic exercise on tumour blood delivery: a systematic review and meta-analysis*. Supportive Care in Cancer, 2022: p. 1-17.
- 48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



Figure 1. Study flow chart





SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	3, 7
	2b	All items from the World Health Organization Trial Registration Data Set	3, 7
Protocol version	3	Date and version identifier	N.A.
Funding	4	Sources and types of financial, material, and other support	17
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1, 2, 17
	5b	Name and contact information for the trial sponsor	17
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	17
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	7

1 **Introduction**

2			
3	Background and	6a	Description of research question and justification for undertaking the trial, including summary of relevant
4	rationale		studies (published and unpublished) examining benefits and harms for each intervention
5			
6		6b	Explanation for choice of comparators
7			
8	Objectives	7	Specific objectives or hypotheses
9			
10	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group),
11			allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)
12			
13			
14	<b>Methods: Participants, interventions, and outcomes</b>		
15			
16	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will
17			be collected. Reference to where list of study sites can be obtained
18			
19	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and
20			individuals who will perform the interventions (eg, surgeons, psychotherapists)
21			
22	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be
23			administered
24		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose
25			change in response to harms, participant request, or improving/worsening disease)
26		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence
27			(eg, drug tablet return, laboratory tests)
28		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial
29			
30	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood
31			pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg,
32			median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen
33			efficacy and harm outcomes is strongly recommended
34			
35	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for
36			participants. A schematic diagram is highly recommended (see Figure)
37			
38			
39			
40			
41			
42			
43			
44			
45			
46			

1 Sample size 14 Estimated number of participants needed to achieve study objectives and how it was determined, including 11  
 2 clinical and statistical assumptions supporting any sample size calculations

3  
 4 Recruitment 15 Strategies for achieving adequate participant enrolment to reach target sample size 11

6  
 7 **Methods: Assignment of interventions (for controlled trials)**

8  
 9 Allocation:

10 Sequence 16a Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any 7  
 11 generation factors for stratification. To reduce predictability of a random sequence, details of any planned restriction  
 12 (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants  
 13 or assign interventions

14 Allocation 16b Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, 7  
 15 concealment opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned  
 16 mechanism

17 Implementation 16c Who will generate the allocation sequence, who will enrol participants, and who will assign participants to 7  
 18 interventions

19 Blinding (masking) 17a Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome 7  
 20 assessors, data analysts), and how

21 17b If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's N.A.  
 22 allocated intervention during the trial

23  
 24  
 25  
 26  
 27  
 28  
 29  
 30  
 31 **Methods: Data collection, management, and analysis**

32 Data collection 18a Plans for assessment and collection of outcome, baseline, and other trial data, including any related 10, 11, Table 1  
 33 methods processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of  
 34 study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known.  
 35 Reference to where data collection forms can be found, if not in the protocol

36 18b Plans to promote participant retention and complete follow-up, including list of any outcome data to be Table 2  
 37 collected for participants who discontinue or deviate from intervention protocols

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	<u>10</u>
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	<u>11-13</u>
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	<u>12, 13</u>
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	<u>12</u>
11				
12				
13				
14	<b>Methods: Monitoring</b>			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	<u>10</u>
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	<u>N.A.</u>
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	<u>8, 14</u>
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	<u>N.A.</u>
29				
30				
31				
32	<b>Ethics and dissemination</b>			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	<u>7</u>
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	<u>13</u>
38				
39				
40				
41				
42				
43				
44				
45				
46				

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	7
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	7
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	10
8				
9				
10	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	17
11				
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	10
14				
15				
16				
17	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	N.A.
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	3
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	N.A.
25				
26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	N.A.
27				
28				
29	<b>Appendices</b>			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	N.A.
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	N.A.
35				
36				

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.